EP1192148A1 - Thiochroman derivatives resisting neurological disorders - Google Patents

Thiochroman derivatives resisting neurological disorders

Info

Publication number
EP1192148A1
EP1192148A1 EP00942179A EP00942179A EP1192148A1 EP 1192148 A1 EP1192148 A1 EP 1192148A1 EP 00942179 A EP00942179 A EP 00942179A EP 00942179 A EP00942179 A EP 00942179A EP 1192148 A1 EP1192148 A1 EP 1192148A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
amino
formula
thiochroman
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00942179A
Other languages
German (de)
French (fr)
Inventor
Deborah Weng Chun Chen
Janet Marie Forst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of EP1192148A1 publication Critical patent/EP1192148A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to chemical compounds, in particular thiochromans, to processes for their preparation and to chemical intermediates useful in such processes.
  • the present invention further relates to thiochromans, to pharmaceutical compositions containing them and to their use in methods of therapeutic treatment of animals including man, in particular in the treatment of neurological disorders.
  • Neurological disorders for which the present compounds are useful, include stroke, head trauma, transient cerebral ischaemic attack, and chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, diabetic neuropathy, amyotrophic lateral sclerosis, multiple sclerosis and AIDS-related dementia.
  • the compounds useful in the present invention act by selectively binding to the [ 3 H]-emopamil binding site.
  • Compounds with selective action at the [ 3 H]-emopamil binding site exhibit fewer associated side effects such as hypotension seen with emopamil or behavioural manifestations seen with ifenprodil. Background
  • Emopamil has classically been thought of as a neuroprotective agent whose efficacy is most likely derived from actions at either voltage-sensitive calcium channels (VSCC) or 5- HT 2 receptors.
  • VSCC voltage-sensitive calcium channels
  • 5- HT 2 receptors 5- HT 2 receptors.
  • verapamil although chemically and pharmacologically very similar to emopamil, is not neuroprotective. While the lack of neuroprotective efficacy by verapamil was initially explained by lack of CNS penetration, recent studies suggest other factors may be involved (Keith et al., Br. J. Pharmacol. 113: 379- 384, 1994).
  • [ 3 H]-Emopamil binding defines a unique high affinity site that is not related to VSCC, is found in the brain, but is most prevalent in the liver (Moebius et al., Mol. Pharmacol. 43: 139-148, 1993). Moebius et al. have termed this the "anti-ischaemic" binding site on the basis of high affinity displacement by several chemically disparate neuroprotective agents. In liver, the [ 3 H] -emopamil binding site is localised to the endoplasmic reticulum.
  • Neuroprotective compounds are known, for example emopamil and ifenprodil, that exhibit high affinity for the [ 3 H] -emopamil binding site. However these are not selective inhibitors and exhibit activity either at neuronal VSCC, the polyamine site of the NMDA receptor (N-Methyl-D-aspartate) and/or the sigma-1 binding site. Summary of the Invention
  • a new method for using compounds having selective action at the [ 3 H] -emopamil binding site and that are neuroprotective without acting directly at either VSCC or NMDA receptors is disclosed.
  • R 1 is hydrogen, C,. 6 alkyl, C 2 . 6 alkenyl or C 2 . 6 alkynyl
  • R 2 and R 3 are independently selected from hydrogen, C,. 6 alkyl, C 2 . 6 alkenyl, C 2 _ 6 alkynyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C 3 . 12 cycloalkyl and C 3 _ 12 cycloalkyl fused to a benzene ring, wherein said C,. 6 alkyl, C 2 . 6 alkenyl, C 2 .
  • 6 alkynyl are optionally substituted with one or more groups selected from halo, nitro, hydroxy, C ⁇ alkoxy, cyano, amino, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, mercapto, sulphamoyl, mesyl, N-C,. 6 alkylamino, N,N-(C,. 6 alkyl) 2 amino, C,. 6 alkoxycarbonyl, N-C ] . 6 alkylcarbamoyl, N,N-(C, .6 alkyl) 2 carbamoyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C 3 .
  • 6 alkyl and a heterocycle or a heteroaryl ring containing an - ⁇ H- group may be optionally substituted on this nitrogen with C,. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,. 6 alkanoyl, C,. 6 alkylsulphonyl or phenylC,.
  • R 4 is selected from halo, hydroxy, C,. 6 alkyl, C,. 6 alkoxy, haloC,. 6 alkyl, cyano, nitro or C 2 . 6 alkenyl;
  • R 5 is C,. 6 alkyl; n is 1 or 2; r is 0, 1, 2, 3 or 4, wherein at each occurrence the values of R 4 may be the same or different; and s is 0, 1 , 2 or 3 wherein at each occurrence the values of R 5 may be the same or different; or a pharmaceutically-acceptable salt or an in vz ' v ⁇ -hydrolysable ester, amide or carbamate thereof.
  • new pharmaceutical compositions containing compounds of formula (I), or in v vo-hydrolysable esters, amides or carbamates thereof, together with a pharmaceutically-acceptable carrier such as an excipient, diluent or stabilizer or combinations thereof as further defined herein are disclosed.
  • a pharmaceutically-acceptable carrier such as an excipient, diluent or stabilizer or combinations thereof as further defined herein.
  • the use of a compound of the formula (I), or a pharmaceutically-acceptable salt or an in v vo-hydrolysable ester, amide or carbamate thereof, in the manufacture of a medicament for use in the inhibition of the [ 3 H]-emopamil binding site in a warm-blooded animal is disclosed.
  • novel compounds are disclosed which are compounds of formula (I) with a proviso wherein in such compounds: if R 1 is hydrogen, R 2 and R 3 and the nitrogen to which they are attached in combination form a morpholine or piperidine ring, n is 1 and s is 0, then r is not 0, or R 4 is not a 5-linked ethoxy moiety.
  • alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as “propyl” are specific for the straight chain version only.
  • alkenyl alkynyl
  • other radicals for example "phenylC,. 6 alkyl
  • phenylC,. 6 alkyl includes 2-phenylethyl, 2-phenylpropyl and 3-phenylpropyl.
  • halo refers to fluoro, chloro, bromo and iodo.
  • aryl refers to an unsaturated carbon ring.
  • aryl is phenyl, naphthyl or biphenyl. More preferably aryl is phenyl.
  • heteroaryl or “heteroaryl ring” refers to, unless otherwise further specified, a monocyclic-, bicyclic- or tricyclic- 5- to 14-membered ring that is unsaturated or partially unsaturated, with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur wherein a -CH 2 - group can optionally be replaced by a -C(O)-, and a ring nitrogen atom may be optionally oxidised to form the N-oxide.
  • heteroaryls examples include thienyl, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyridyl-N-oxide, oxopyridyl, oxoquinolyl, pyrimidinyl, pyrazinyl, oxopyrazinyl, pyridazinyl, indolinyl, benzofliranyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolinyl, quinazolinyl, xanthenyl, quinoxalinyl, indazolyl, benzofliranyl and cinnolinolyl.
  • heterocyclyl or “heterocyclic ring” refers to, unless otherwise further specified, a mono- or bicyclic- 5- to 14-membered ring, that is totally saturated, with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur wherein a -CH 2 - group can optionally be replaced by a -C(O)-.
  • heterocyclyls include morpholinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, homopiperidinyl, homopiperazinyl and quinuclidinyl.
  • C,. 6 alkyl examples include C,. 4 alkyl such as methyl, ethyl, isopropyl and t-butyl; examples of phenylC ,. 6 alkyl include phenylC 2 . 6 alkyl such as phenylC ,. 4 alkyl such as phenylC 2 _
  • alkyl such as benzyl, phenylethyl and phenylpropyl
  • examples of C,. 6 alkoxy carbonyl include methoxycarbonyl, ethoxycarbonyl, n- and t- butoxy carbonyl
  • examples of C,. 6 alkoxy include methoxy, ethoxy and propoxy
  • examples of C,. 6 alkanoylamino include formamido, acetamido and propionylamino
  • examples of C ] . 6 alkylS(O) a where a is 0, 1 or 2 include C,.
  • alkylsulphonyl methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl;
  • examples of C, .6 alkylsulphonyl include mesyl and ethylsulphonyl;
  • examples of C,. 6 alkanoyl include propionyl and acetyl;
  • examples of N-C,. 6 alkylamino include N-methylamino and N-ethylamino; examples of N,N-(C,.
  • examples of C 3.12 cycloalkyl include cyclopropyl and cyclohexyl; examples of C 3.I2 cycloalkyl fused to a benzene ring are 1,2,3,4-tetrahydronaphthyl and 2,3- dihydroindenyl; examples of C 2 . 6 alkenyl include vinyl, allyl and 1-propenyl; examples of C 2 . 6 alkynyl include ethynyl, 1-propynyl and 2-propynyl; examples of haloC 2 .
  • N-(C ⁇ . 6 alkyl)sulphamoyl examples include N-methylsulphamoyl and N-ethylsulphamoyl; examples of N,N-(C, .6 alkyl) 2 sulphamoyl include N,N-dimethylsulphamoyl and N-methyl-N- ethylsulphamoyl; examples of N-(C,. 6 alkyl)carbamoyl include N-methylcarbamoyl and N-ethylcarbamoyl; examples of N,N-(C,.
  • R 1 is hydrogen, C,. 6 alkyl or C 2 . 6 alkenyl. More preferably R 1 is hydrogen, C,. 4 alkyl or C 2 . 4 alkenyl. Particularly R 1 is hydrogen, methyl, ethyl or allyl. More particularly R 1 is hydrogen, methyl or ethyl.
  • R' is methyl.
  • R 2 and R 3 are independently selected from hydrogen, optionally substituted C,. 6 alkyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C 3 . 12 cycloalkyl and C 3 . 12 cycloalkyl fused to a benzene ring wherein said optional substituents are chosen from one or more groups selected from halo, nitro, hydroxy, C,. 6 alkoxy, cyano, amino, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, mercapto, sulphamoyl, mesyl, N-C,.
  • any aryl, heteroaryl or heterocycle may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,. 6 alkoxy, C,. 6 alkanoyl, C,. 6 alkanoyloxy, N-(C,. 6 alkyl)amino, N,N-(C ⁇ .
  • R 2 and R 3 and the nitrogen atom to which they are attached in combination form a ring selected from 1,2,3,4- tetrahydroisoquinolinyl, morpholinyl, piperidinyl, pyrrolidinyl, homopiperidinyl and wherein said ring may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,.
  • R 2 and R 3 are independently selected from hydrogen, aryl and C,. 6 alkyl optionally substituted with aryl; or R 2 and R 3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring wherein a heterocyclic ring containing an - ⁇ H- group may be optionally substituted on this nitrogen with C,. 6 alkyl.
  • R 2 and R 3 are independently selected from hydrogen, methyl, ethyl, isopropyl, phenyl or benzyl, or R 2 and R 3 and the nitrogen atom to which they are attached in combination form a pyrrolidin-1-yl, piperidin-1-yl, 4-methylpiperazin-l-yl, morpholino or 1 ,2,3 ,4-tetrahydroisoquinol-2-yl ring.
  • R 2 and R 3 are independently selected from methyl or benzyl, or R 2 and R 3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, morpholino, 4- methylpiperazin-1-yl, or l,2,3,4-tetrahydroisoquinol-2-yl ring.
  • R 2 and R 3 are independently selected from methyl or benzyl, or R 2 and R 3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, morpholino or l,2,3,4-tetrahydroisoquinol-2-yl ring.
  • r is 0.
  • s is 0.
  • n 1
  • n is 2. Therefore in a preferred aspect of the invention there is provided an compound of formula (I) as depicted above wherein:
  • R 1 is hydrogen, C,. 6 alkyl or C 2 . 6 alkenyl
  • R 2 and R 3 are independently selected from hydrogen, aryl and C,. 6 alkyl optionally substituted with aryl, or R 2 and R 3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring wherein a heterocyclic ring containing an - NH- group may be optionally substituted on this nitrogen with C,. 6 alkyl; r is 0; s is 0; and n is 1 or 2; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
  • R 1 is hydrogen, methyl, ethyl or allyl
  • R 2 and R 3 are independently selected from methyl or benzyl, or R 2 and R 3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, morpholino, 4- methylpiperazin-1-yl, or l,2,3,4-tetrahydroisoquinol-2-yl ring
  • r is 0
  • s is 0
  • n is 1 or 2
  • R' is methyl
  • R 2 and R 3 are independently selected from methyl or benzyl, or R 2 and R 3 and the nitrogen to which they are attached in combination form a piperidin- 1 -yl, morpholino or 1 ,2,3,4-tetrahydroisoquinol-2-yl ring; r is 0; s is 0; and n is 1 or 2; or a pharmaceutically-acceptable salt or and in vzvo-hydrolysable ester, amide or carbamate thereof.
  • Preferred compounds of the invention are those of Examples.
  • a preferred aspect of the invention relates to any one of the Examples.
  • Preferred aspects of the invention relate to a compound or a pharmaceutically- acceptable salt thereof.
  • Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid.
  • suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N- methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or amino acids for example lysine.
  • a preferred pharmaceutically-acceptable salt is a sodium salt.
  • the compounds of formula (I) possess a chiral centre at the 4-position of the thiochroman ring. Certain compounds of formula (I) may also have other chiral centres, for example certain of the values of R 2 , R 3 , R 4 , R 5 and certain of the optional substituents may possess chiral centres. It is to be understood that the invention encompasses all such optical isomers and diasteroisomers of compounds of formula (I) that inhibit the [ 3 H]-emopamil binding site.
  • the invention further relates to all tautomeric forms of the compounds of formula (I).
  • esters, amides and carbamates are compounds that hydrolyse in the human body to produce the parent compound. Such esters, amides and carbamates can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vzvo-hydrolysable amides and carbamates include N-carbomethoxy and N-acetyl.
  • An in vzvo-hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
  • Suitable pharmaceutically-acceptable esters for carboxy include C,. 6 alkoxymethyl esters for example methoxymethyl, C,. 6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3 . 8 cycloalkoxy-carbonyloxyC,. 6 alkyl esters for example 1 -cyclohexylcarbonyloxy ethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3- dioxolen-2-onylmethyl; and C,. 6 alkoxycarbonyloxyethyl esters for example 1- methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
  • An in vzvo-hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
  • ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2- dimethylpropionyloxymethoxy.
  • a selection of in vzvo-hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)- N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
  • Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof which process (wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, r and s are, unless otherwise specified, as defined in formula (I)) comprises of: a) reacting a ketone of formula (II):
  • L is a suitable displaceable group, with an amine of formula (VII); or h) if R 1 is not hydrogen, reacting a compound of formula (VIII) with a compound of formula (XIII):
  • L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4- sulphonyloxy group.
  • G is a suitable displaceable group
  • suitable values for G are C ⁇ alkoxy, for example methoxy or ethoxy.
  • Specific reaction conditions for the reactions a), b), c) and d), above, are as follows.
  • Ketones or aldehydes may be reacted with amines under standard reductive amination conditions.
  • Imine formation may optionally be assisted with a Lewis acid for example titanium tetrachloride, in an inert solvent for example toluene.
  • the reduction may occur for example in the presence of a reducing agent such as hydrogen and a hydrogenation catalyst (for example palladium on carbon), or zinc and hydrochloric acid, or sodium cyanoborohydride, or sodium triacetoxyborohydride, or sodium borohydride, iron pentacarbonyl and alcoholic potassium hydroxide, or borane and pyridine or formic acid.
  • a suitable solvent such as an alcohol, for example methanol or ethanol, and at a temperature in the range of 0-50 °C, preferably at or near room temperature.
  • an optically active form of a compound of the formula (I) When an optically active form of a compound of the formula (I) is required, it may be obtained, for example, by carrying out one of the aforesaid procedures using an optically active starting material or by resolution of a racemic form of said compound using a conventional procedure.
  • An example of converting one compound of formula (I) into another compound of formula (I) is the conversion of R 1 , R 2 or R 3 when they are hydrogen to a different R 1 , R 2 , or R 3 .
  • an alkyl group could be introduced by standard alkylation or reductive amination techniques, such as those described above.
  • aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
  • modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • a base such as sodium hydroxide
  • a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
  • the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
  • a compound of the formula (I) or a pharmaceutically-acceptable salt or in vzvo-hydrolysable ester, amide or carbamate thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
  • the pharmaceutical compositions of compounds of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation.
  • the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.
  • a preferred route of administration is intravenously in sterile isotonic solution.
  • composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to hereinabove.
  • compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.05 to 75 mg/kg body weight (and preferably of 0.1 to 30 mg/kg body weight) is received.
  • This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.
  • unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.
  • a pharmaceutical composition which comprises a compound of the formula (I) as defined hereinbefore or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof, in association with a pharmaceutically-acceptable excipient or carrier.
  • a further feature of the present invention is a compound of formula (I) and pharmaceutically-acceptable salts or an in vzvo-hydrolysable ester, amide or carbamate thereof, for use as a medicament to inhibit the [ 3 H]-emopamil binding site in a warm-blooded animal such as a human being.
  • a method of inhibiting of the [ 3 H]-emopamil binding site in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically-acceptable salt or an in vivo- hydrolysable ester, amide or carbamate thereof, as defined hereinbefore.
  • the reaction mixture contained: Assay buffer: 10 mM Tris-HCl, 0.1 mM phenylmethylsulphonyl fluoride (PMSF), 0.2% bovine serum albumin (BSA), pH 7.4 at 4 °C.
  • Assay buffer 10 mM Tris-HCl, 0.1 mM phenylmethylsulphonyl fluoride (PMSF), 0.2% bovine serum albumin (BSA), pH 7.4 at 4 °C.
  • Radioligand 0.96 nM (-)- 3 H-emopamil (Amersham).
  • Guinea pig liver membranes 40mg/mL original wet weight.
  • Compounds 1-300 nM. Total volume: 500 ⁇ L.
  • This mixture was incubated for 60 minutes at 37 °C. The incubation was terminated by filtering with a Brandel Cell Harvester over Whatman GF/C filters that had been soaked for at least 120 minutes in 0.3% polyethylenimine (PEI) and washed three times with 5 mL of wash buffer containing 10 mM Tris-HCl, 10 mM MgCl 2 , 0.2% BSA, pH 7.4 at 25 °C.
  • PEI polyethylenimine
  • the assay tubes contained the following: assay buffer: 50 mM Hepes, 0.2% BSA, pH 7.4 radioligand: l ⁇ M 3 H-D888 (Amersham) rat cortical membranes: 6 mg/mL original wet weight compounds: 0.3-100 ⁇ M Total volume: 1000 ⁇ L.
  • This mixture was incubated for 60 minutes at 25 °C.
  • the assay was terminated by filtering with a Brandel Cell Harvester over Whatman GF/C filters that had been soaked for at least 120 minutes in 0.3% polyefhylenamine (PEI) and washed three times with 5 mL of wash buffer containing 20 mM Hepes, 20 mM MgCl 2 , pH 7.4. Specific binding was measured with 10 ⁇ M methoxyverapamil (D-600).
  • This assay was used to determine in vitro selectivity of compounds vs. L-type voltage sensitive calcium channels, i.e. high affinity for the 3 H-D888 binding site would show a lack of selectivity.
  • Rat brain cortical membrane preparation Male Sprague-Dawley Rats were sacrificed by decapitation and the brains were quickly excised. The cerebellum and brain stem were removed and discarded; and the rest of the brain was rinsed in 320 mM sucrose. The brain was then homogenised in a 10-fold volume of 320 mM sucrose with a motor driven Teflon-glass homogeniser using 10 strokes on ice. The homogenate was spun at 1000 x g for 10 minutes at 4 °C in a SS-34 rotor. The supernatant was then spun at 29,000 x g for 20 minutes. The resulting pellet was resuspended in membrane buffer (5 mM Hepes, 0.2% BSA, pH 7.4) to a final concentration of 60 mg original wet weight/mL.
  • Gerbil Global Model of Cerebral Ischaemia Gerbil Global Model of Cerebral Ischaemia
  • mice Male Mongolian gerbils (Charles River) weighing 60-70 grams are used in these experiments. They are housed in individual cages with food (Purina Rodent Chow) and water available ad libitum. The animal room is maintained at 23 ⁇ 2 °C, and is on an automatic 12 hour light cycle.
  • the gerbils are brought to the surgical suite and dosed intraperitoneally with the test agent or vehicle, forty five minutes prior to surgery. Drugs are administered at a volume of 5 mL/kg (intraperitoneal). Vehicle is generally saline, with sodium phosphate added to adjust pH, if needed. Forty-five minutes after dosing the gerbils are anaesthetised with halothane (3.3%) which is delivered along with oxygen (1.5 1/M) through a face mask. After the gerbils are anaesthetised, halothane is continued at a maintenance level of 1.5-2 % along with oxygen. The ventral surface of the neck is shaved and cleaned with alcohol.
  • Surgical procedures are carried out on a thermostat-controlled heating pad set to 37 °C.
  • An incision is made in the neck, the carotid arteries are dissected away from the surrounding tissue, and isolated with a 5 cm length of Silastic tubing.
  • both arteries have been isolated they are clamped with microaneurysm clips (Roboz Instruments).
  • the arteries are visually inspected to determine that the blood flow has been stopped. After 5 minutes the clips are gently removed from the arteries and blood flow begins again.
  • a sham control group is treated identically but is not subjected to carotid artery occlusion.
  • the incisions are closed with suture and the gerbils removed from the anaesthesia masks and placed on another heating pad to recover from the anaesthesia. When they have regained the righting reflex and are beginning to walk around, they are again dosed with the test compound and returned to their home cages. This occurs approximately five minutes after the end of surgery.
  • gerbils Twenty-four hours post ischaemia gerbils are tested for spontaneous locomotor activity, using a Photobeam Activity System from San Diego Instruments. They are individually placed in Plexiglas chambers measuring 27.5 cm x 27.5 cm x 15 cm deep. The chambers are surrounded by photocells, and every time a beam is broken one count is recorded. Each gerbil is tested for two hours, and cumulative counts are recorded at 30, 60, 90, and 120 minutes. Mean counts are recorded for each group and drug groups are compared to control with an ANOVA and Bonferroni post test. After each gerbil is tested it is returned to its home cage. At this time gerbils are also observed for any changes from normal behaviour.
  • the MCA trunk was ligated immediately above the rhinal fissure with 10-0 suture. Complete interruption of blood flow was confirmed under an operating microscope. Both common carotid arteries were then occluded using nontraumatic aneurysm clips. After a predetermined duration of ischaemia (45 min), blood flow was restored in all three arteries. Twenty-four hours post occlusion, rats were killed under ketamine anaesthesia by intracardiac perfusion with 200 mL of 0.9% NaCl. The brain was removed and processed with 2% triphenyltetrazolium chloride to identify and quantitate the infarcted brain region. Compounds were administered by intravenous infusion for 4 hours. Data
  • DMSO dimethylsulphoxide
  • CDC1 3 is deuterated chloroform
  • m/s is mass spectroscopy
  • THF is tetrahydrofuran
  • DCM is dichloromethane
  • Com Av is commercially available; and SM is starting material.
  • Example 3 4-[2-(Piperidin- 1 -yl)ethyl(N-ethyl amino]thiochroman A solution of 4-[2-(piperidin-l-yl)ethyl(N-acetyl)amino]thiochroman (Method 1)
  • Example 6 4-(3-M ⁇ holin-4-ylpropylamino)thiochroman, 1.68 (m, 2H), 1.93 (m, IH), 2.40 (m, 7H), 2.70 (m, 2H), 2.87 (dt, IH), 3.34 (td, IH), 3.68 (t, 4H), 3.74 (m, IH), 7.20-6.99 (m, 4H).
  • Example 7 4-(2-Dimethylaminoethylamino)thiochroman, 2.00-1.94 (m, 2H), 2.21 (s, 6H),
  • Example 8 4-(2-Isopropylaminoethylamino)thiochroman, 1.06 (d, 6H), 1.76 (br s, 2H), 1.93
  • Example 9 4-((2-Pyrrolidin-l-ylethyl)amino)thiochroman, 1.60 (br s, IH), 1.75 (m, 4H),
  • Example 10 4-(2-Diethylaminoethylamino)thiochroman, 0.98 (t, 6H), 1.95 (m, IH), 2.31 (m,
  • Example 1 1 4-((3-Piperidin-l-ylpropyl)amino)thiochroman, 1.80-1.30 (m, 9H), 1.92 (m,
  • Example 12 4-((3-(4-Methylpiperazin-l-yl)propyl)amino)thiochroman, 1.69 (m, 2H), 1.92 (m, IH), 2.27 (s, 3H), 2.42 (m, 1 IH), 2.72 (m, 2H), 2.86 (dt, IH), 3.34 (td, IH), 3.73 (t, IH),
  • Example 13 4-(2-Phenylaminoethylamino)thiochroman, 1.55 (br s, IH), 1.97 (m, IH), 2.31
  • Example 14 4-(2-Benzylaminoethylamino)thiochroman, 1.52 (br s, 2H), 1.94 (m, IH), 2.30
  • Example 15 4-(Methyl-(3-(4-methylpiperazin-l-yl)propyl)amino)thiochroman, 1.68 (m, 2H),
  • Example 18 (S)-4-(N'-(2-(3,4-Dihydro-lH-isoquinolin-2-yl)-N-ethyl)amino)thiochroman, 2.12 (m, 1 ⁇ ), 2.24 (m, 1 ⁇ ), 2.32 (s, 3 ⁇ ), 2.73 (m, 6H), 2.89 (t, 2H), 3.10 (dd, 2H), 3.62 (s, 2H), 3.81 (dd, IH), 7.15-6.97 (m, 7H), 7.62 (m, IH).
  • Example 22 was prepared by the method of Example 1.
  • Example 22 (S)-4-(N'-(2-(l,3-Dihydroisoindol-2-yl)ethyl)-N'-methylamino)thiochroman, 1.88-2.05 (m, IH), 2.10-2.29 (m, 4H), 2.53-2.67 (m, 2H), 2.71-2.90 (m, 2H), 3.03-3.13 (m,
  • Example 23 (5)-4-(N'-(2-(l,3-Dihydroisoindol-2-yl)ethyl)amino)thiochroman, 1.72-1.93 (m,
  • Example 24 (5)-4-((2-Azepan-l-ylethyl)amino)thiochroman, 1.37-1.67 (m, 8H), 1.67-1.92
  • Example 27 2.07 (m, IH), 2.58 (m, 5H), 2.69 (m, 2H), 3.35-3.00 (m, 4H), 3.64 (m, 4H), 4.48 (m, 1 H), 6.13 (s, 4H), 7.32-7.14 (m, 3H), 7.44 (m, 1 H).
  • Example 28 2.09 (m, 2H), 2.24 (s, 3H), 2.78 (m, IH), 3.17-2.93 (m, 6H), 3.29 (m, IH), 3.41 (m, 2H), 3.89 (t, IH), 4.36 (s, 2H), 6.14 (s, 4H), 7.11 (m, 4H), 7.25 (m, 3H), 7.54 (d, IH).
  • Reference Example 1 4- " 2-(Piperidin- 1 -vDethylamino "
  • the filtrate from the HC1 precipitation step was stored at 4 °C for 16 hours during which time further precipitate of (+)-4-[2- chloroacetamidojthiochroman occurred, this was removed by filtration through a Whatman 113 filter paper and the clear filtrate adjusted to pH 12 with sodium hydroxide (40% w/v).
  • the solution was then extracted with n-hexane (2 x 1000 mL) to recover unreacted (-)-4- aminothiochroman.
  • the hexane was recovered, dried with anhydrous sodium sulphate and filtered.
  • Method 6 (a) A suspension of N-(t-butoxycarbonyl)glycine (2.35, 1.34 x 10 "2 mole) and 1- hydroxybenzotriazole (1.90 g, 1.41 x 10 "2 mole) in DCM (50 mL) was treated with l-[3- dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (3.05 g, 1.59 x 10 "2 mole) and triethylamine (2.3 mL, 1.65 x 10 "2 mole), respectively. Immediately, a solution of (S)-4- aminothiochroman (2.18 g, 1.32 x 10 "2 mole) in DCM (30 mL) was added.
  • Example 29 2.03-2.27 (m, 5H), 2.50 (s, 1.2H), 2.75 (s, 1.8H), 2.94-3.06 (m, IH), 3.10-3.70 (m, 5H), 5.23-5.33 (m, 0.4H), 5.61-5.72 (m, 0.6H), 6.88-7.43 (m, 9H).
  • Example 30 1.59-1.77 (m, 4H), 2.05-2.34 (m, 2H), 2.43-2.61 (m, 5.2H), 2.75 (s, 1.8H), 2.95-
  • Example 32 1.43-1.65 (s, 8H), 1.95-2.24 (m, 2H), 2.57-2.73 (m, 4H), 3.00-3.17 (m, 4H),
  • Example 33 1.96-2.25 (m, 5H), 2.96-3.10 (m, 4H), 3.58 (s, 2H), 5.00-5.10 (m, IH), 6.95- 7.38 (m, 9H), 8.16-8.24 (m, IH).
  • HPMC Hydroxypropylmethylcellulose
  • a compound of Formula (I) is dissolved in an isotonic sterile solution (5 mg/mL).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Methods for the use of compounds of formula (I) for treatment of neurological disorders, wherein n, r and s are as defined in the specification and R?1, R2, R3, R4 and R5¿ are various substituents, also as defined in the specification, such compounds and pharmaceutical compositions containing such compounds.

Description

THI0CHR0MAN DERIVATIVES AGAINST NEUROLOGICAL DISORDERS
The present invention relates to chemical compounds, in particular thiochromans, to processes for their preparation and to chemical intermediates useful in such processes. The present invention further relates to thiochromans, to pharmaceutical compositions containing them and to their use in methods of therapeutic treatment of animals including man, in particular in the treatment of neurological disorders.
Neurological disorders, for which the present compounds are useful, include stroke, head trauma, transient cerebral ischaemic attack, and chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, diabetic neuropathy, amyotrophic lateral sclerosis, multiple sclerosis and AIDS-related dementia. The compounds useful in the present invention act by selectively binding to the [3H]-emopamil binding site. Compounds with selective action at the [3H]-emopamil binding site exhibit fewer associated side effects such as hypotension seen with emopamil or behavioural manifestations seen with ifenprodil. Background
Emopamil has classically been thought of as a neuroprotective agent whose efficacy is most likely derived from actions at either voltage-sensitive calcium channels (VSCC) or 5- HT2 receptors. An apparent paradox to this logic is that verapamil, although chemically and pharmacologically very similar to emopamil, is not neuroprotective. While the lack of neuroprotective efficacy by verapamil was initially explained by lack of CNS penetration, recent studies suggest other factors may be involved (Keith et al., Br. J. Pharmacol. 113: 379- 384, 1994).
[3H]-Emopamil binding defines a unique high affinity site that is not related to VSCC, is found in the brain, but is most prevalent in the liver (Moebius et al., Mol. Pharmacol. 43: 139-148, 1993). Moebius et al. have termed this the "anti-ischaemic" binding site on the basis of high affinity displacement by several chemically disparate neuroprotective agents. In liver, the [3H] -emopamil binding site is localised to the endoplasmic reticulum.
Neuroprotective compounds are known, for example emopamil and ifenprodil, that exhibit high affinity for the [3H] -emopamil binding site. However these are not selective inhibitors and exhibit activity either at neuronal VSCC, the polyamine site of the NMDA receptor (N-Methyl-D-aspartate) and/or the sigma-1 binding site. Summary of the Invention
In one aspect of the present invention a new method for using compounds having selective action at the [3H] -emopamil binding site and that are neuroprotective without acting directly at either VSCC or NMDA receptors is disclosed.
Compounds of the invention that have selective action at the [3H]-emopamil binding site are compounds of formula (I):
wherein:
R1 is hydrogen, C,.6alkyl, C2.6alkenyl or C2.6alkynyl; R2 and R3 are independently selected from hydrogen, C,.6alkyl, C2.6alkenyl, C2_ 6alkynyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3.12cycloalkyl and C3_ 12cycloalkyl fused to a benzene ring, wherein said C,.6alkyl, C2.6alkenyl, C2.6alkynyl, are optionally substituted with one or more groups selected from halo, nitro, hydroxy, C ^alkoxy, cyano, amino, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, mercapto, sulphamoyl, mesyl, N-C,.6alkylamino, N,N-(C,.6alkyl)2amino, C,.6alkoxycarbonyl, N-C].6alkylcarbamoyl, N,N-(C,.6alkyl)2carbamoyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3. 12cycloalkyl and C3.]2cycloalkyl fused to a benzene ring; and wherein any aryl, heteroaryl, heterocycle, C3.12cycloalkyl and C3.12cycloalkyl fused to a benzene ring may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N- (C,.6alkyl)amino, N,N-(C,.6alkyl)2amino, C,.6alkanoylamino, N-(C,.6alkyl)carbamoyl, N,N-(C,_ 6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,.6alkoxycarbonyl, N-(C,. 6alkyl)sulphamoyl, NN-(C1.6alkyl)2sulphamoyl and phenylC,.6alkyl; and a heterocycle or a heteroaryl ring containing an -ΝH- group may be optionally substituted on this nitrogen with C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C,.6alkylsulphonyl or phenylC,.6alkyl; or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring and wherein said heterocyclic or heteroaryl ring is optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N- (C,_6alkyl)amino, N,N-(C]_6alkyl)2amino, C,.6alkanoylamino, N-(C,.6alkyl)carbamoyl, NN-(C,_ 6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,.6alkoxy carbonyl, N-(C,. 6alkyl)sulphamoyl, N,N-(C,.6alkyl)2sulphamoyl or phenylC,.6alkyl; and a heterocyclic or a heteroaryl ring containing an -ΝH- group is optionally substituted on this nitrogen with C,_ 6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C,.6alkylsulphonyl;
R4 is selected from halo, hydroxy, C,.6alkyl, C,.6alkoxy, haloC,.6alkyl, cyano, nitro or C2.6alkenyl;
R5 is C,.6alkyl; n is 1 or 2; r is 0, 1, 2, 3 or 4, wherein at each occurrence the values of R4 may be the same or different; and s is 0, 1 , 2 or 3 wherein at each occurrence the values of R5 may be the same or different; or a pharmaceutically-acceptable salt or an in vz'vø-hydrolysable ester, amide or carbamate thereof.
In another aspect of the present invention, new pharmaceutical compositions containing compounds of formula (I), or in v vo-hydrolysable esters, amides or carbamates thereof, together with a pharmaceutically-acceptable carrier such as an excipient, diluent or stabilizer or combinations thereof as further defined herein are disclosed. In a further aspect of the present invention, the use of a compound of the formula (I), or a pharmaceutically-acceptable salt or an in v vo-hydrolysable ester, amide or carbamate thereof, in the manufacture of a medicament for use in the inhibition of the [3H]-emopamil binding site in a warm-blooded animal is disclosed.
In yet a further aspect of the present invention, novel compounds are disclosed which are compounds of formula (I) with a proviso wherein in such compounds: if R1 is hydrogen, R2 and R3 and the nitrogen to which they are attached in combination form a morpholine or piperidine ring, n is 1 and s is 0, then r is not 0, or R4 is not a 5-linked ethoxy moiety.
Detailed Description of the Invention In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. A similar convention applies to "alkenyl", "alkynyl" and other radicals, for example "phenylC,.6alkyl" includes 2-phenylethyl, 2-phenylpropyl and 3-phenylpropyl. The term "halo" refers to fluoro, chloro, bromo and iodo. The term aryl refers to an unsaturated carbon ring. Preferably aryl is phenyl, naphthyl or biphenyl. More preferably aryl is phenyl.
The term "heteroaryl" or "heteroaryl ring" refers to, unless otherwise further specified, a monocyclic-, bicyclic- or tricyclic- 5- to 14-membered ring that is unsaturated or partially unsaturated, with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur wherein a -CH2- group can optionally be replaced by a -C(O)-, and a ring nitrogen atom may be optionally oxidised to form the N-oxide. Examples of such heteroaryls include thienyl, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridyl, pyridyl-N-oxide, oxopyridyl, oxoquinolyl, pyrimidinyl, pyrazinyl, oxopyrazinyl, pyridazinyl, indolinyl, benzofliranyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolinyl, quinazolinyl, xanthenyl, quinoxalinyl, indazolyl, benzofliranyl and cinnolinolyl.
The term "heterocyclyl" or "heterocyclic ring" refers to, unless otherwise further specified, a mono- or bicyclic- 5- to 14-membered ring, that is totally saturated, with up to five ring heteroatoms selected from nitrogen, oxygen and sulphur wherein a -CH2- group can optionally be replaced by a -C(O)-. Examples of such heterocyclyls include morpholinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, homopiperidinyl, homopiperazinyl and quinuclidinyl.
Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. In the present invention, examples of C,.6alkyl include C,.4alkyl such as methyl, ethyl, isopropyl and t-butyl; examples of phenylC ,.6alkyl include phenylC2.6alkyl such as phenylC ,.4alkyl such as phenylC2_
4alkyl such as benzyl, phenylethyl and phenylpropyl; examples of C,.6alkoxy carbonyl include methoxycarbonyl, ethoxycarbonyl, n- and t- butoxy carbonyl; examples of C,.6alkoxy include methoxy, ethoxy and propoxy; examples of C,.6alkanoylamino include formamido, acetamido and propionylamino; examples of C].6alkylS(O)a where a is 0, 1 or 2 include C,.6alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl; examples of C,.6alkylsulphonyl include mesyl and ethylsulphonyl; examples of C,.6alkanoyl include propionyl and acetyl; examples of N-C,.6alkylamino include N-methylamino and N-ethylamino; examples of N,N-(C,.6alkyl)2amino include N,N-dimethylamino, N,N-diethylamino and N- ethyl-N-methylamino; examples of C3.12cycloalkyl include cyclopropyl and cyclohexyl; examples of C3.I2cycloalkyl fused to a benzene ring are 1,2,3,4-tetrahydronaphthyl and 2,3- dihydroindenyl; examples of C2.6alkenyl include vinyl, allyl and 1-propenyl; examples of C2.6alkynyl include ethynyl, 1-propynyl and 2-propynyl; examples of haloC2.6alkyl include 2-chloroethyl and 2-bromopropyl; examples of N-(Cι.6alkyl)sulphamoyl include N-methylsulphamoyl and N-ethylsulphamoyl; examples of N,N-(C,.6alkyl)2sulphamoyl include N,N-dimethylsulphamoyl and N-methyl-N- ethylsulphamoyl; examples of N-(C,.6alkyl)carbamoyl include N-methylcarbamoyl and N-ethylcarbamoyl; examples of N,N-(C,.6alkyl)2carbamoyl include N,N-dimethylcarbamoyl and N-methyl-N- ethylcarbamoyl, and examples of C,.6alkanoyloxy include propionyloxy, acetyloxy and formyloxy. Preferably R1 is hydrogen, C,.6alkyl or C2.6alkenyl. More preferably R1 is hydrogen, C,.4alkyl or C2.4alkenyl. Particularly R1 is hydrogen, methyl, ethyl or allyl. More particularly R1 is hydrogen, methyl or ethyl.
In a particularly preferred aspect R' is methyl. In one aspect of the invention, preferably R2 and R3 are independently selected from hydrogen, optionally substituted C,.6alkyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3.12cycloalkyl and C3.12cycloalkyl fused to a benzene ring wherein said optional substituents are chosen from one or more groups selected from halo, nitro, hydroxy, C,. 6alkoxy, cyano, amino, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, mercapto, sulphamoyl, mesyl, N-C,.6alkylamino, N,N-(C,.6alkyl)2amino, C].6alkoxycarbonyl, N-C,_ 6alkylcarbamoyl, N,N-(C,.5alkyl)2carbamoyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3.12cycloalkyl and C3.12cycloalkyl fused to a benzene ring; and wherein any aryl, heteroaryl or heterocycle may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,. 6alkanoyl, C,.6alkanoyloxy, N-(C,.6alkyl)amino, N,N-(Cι.6alkyl)2amino, C,.6alkanoylamino, N- (C,.6alkyl)carbamoyl, NN-(C1.6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,_ 6alkoxy carbonyl, N-(C,.6alkyl)sulphamoyl, NN-(Cι.6alkyl)2sulphamoyl and phenylC,.6alkyl; and a heterocycle or a heteroaryl ring containing an -ΝH- group may be optionally substituted on this nitrogen with C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C,.6alkylsulphonyl or phenylC,.6alkyl.
In another aspect of the invention preferably R2 and R3 and the nitrogen atom to which they are attached in combination form a ring selected from 1,2,3,4- tetrahydroisoquinolinyl, morpholinyl, piperidinyl, pyrrolidinyl, homopiperidinyl and wherein said ring may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N-(C,.6alkyl)amino, NN-(C1.6alkyl)2amino, C,.6alkanoylamino, N-(C,_ 6alkyl)carbamoyl, N,N-(C,.6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,. 6alkoxycarbonyl, N-(C,.6alkyl)sulphamoyl, NN-(C,.6alkyl)2sulphamoyl or phenylC,.6alkyl.
In a further aspect of the invention, preferably R2 and R3 are independently selected from hydrogen, aryl and C,.6alkyl optionally substituted with aryl; or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring wherein a heterocyclic ring containing an -ΝH- group may be optionally substituted on this nitrogen with C,.6alkyl. More preferably R2 and R3 are independently selected from hydrogen, methyl, ethyl, isopropyl, phenyl or benzyl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a pyrrolidin-1-yl, piperidin-1-yl, 4-methylpiperazin-l-yl, morpholino or 1 ,2,3 ,4-tetrahydroisoquinol-2-yl ring. Particularly R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, morpholino, 4- methylpiperazin-1-yl, or l,2,3,4-tetrahydroisoquinol-2-yl ring.
More particularly R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, morpholino or l,2,3,4-tetrahydroisoquinol-2-yl ring.
Preferably r is 0.
Preferably s is 0.
In one aspect of the invention preferably n is 1.
In another aspect of the invention preferably n is 2. Therefore in a preferred aspect of the invention there is provided an compound of formula (I) as depicted above wherein:
R1 is hydrogen, C,.6alkyl or C2.6alkenyl;
R2 and R3 are independently selected from hydrogen, aryl and C,.6alkyl optionally substituted with aryl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring wherein a heterocyclic ring containing an - NH- group may be optionally substituted on this nitrogen with C,.6alkyl; r is 0; s is 0; and n is 1 or 2; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
In a more preferred aspect of the invention there is provided a compound of the formula (I) as depicted above wherein:
R1 is hydrogen, methyl, ethyl or allyl; R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, morpholino, 4- methylpiperazin-1-yl, or l,2,3,4-tetrahydroisoquinol-2-yl ring; r is 0; s is 0; and n is 1 or 2; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
In a particular aspect of the invention there is provided a compound of formula (I) as depicted above wherein:
R' is methyl;
R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen to which they are attached in combination form a piperidin- 1 -yl, morpholino or 1 ,2,3,4-tetrahydroisoquinol-2-yl ring; r is 0; s is 0; and n is 1 or 2; or a pharmaceutically-acceptable salt or and in vzvo-hydrolysable ester, amide or carbamate thereof.
Preferred compounds of the invention are those of Examples.
A preferred aspect of the invention relates to any one of the Examples.
Preferred aspects of the invention relate to a compound or a pharmaceutically- acceptable salt thereof.
Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N- methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or amino acids for example lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is a sodium salt. The compounds of formula (I) possess a chiral centre at the 4-position of the thiochroman ring. Certain compounds of formula (I) may also have other chiral centres, for example certain of the values of R2, R3, R4, R5 and certain of the optional substituents may possess chiral centres. It is to be understood that the invention encompasses all such optical isomers and diasteroisomers of compounds of formula (I) that inhibit the [3H]-emopamil binding site.
The invention further relates to all tautomeric forms of the compounds of formula (I).
It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated and unsolvated forms.
In vzvo-hydrolysable esters, amides and carbamates are compounds that hydrolyse in the human body to produce the parent compound. Such esters, amides and carbamates can be identified by administering, for example intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vzvo-hydrolysable amides and carbamates include N-carbomethoxy and N-acetyl.
An in vzvo-hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
Suitable pharmaceutically-acceptable esters for carboxy include C,.6alkoxymethyl esters for example methoxymethyl, C,.6alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3.8cycloalkoxy-carbonyloxyC,.6alkyl esters for example 1 -cyclohexylcarbonyloxy ethyl; l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3- dioxolen-2-onylmethyl; and C,.6alkoxycarbonyloxyethyl esters for example 1- methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
An in vzvo-hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and α-acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group. Examples of α-acyloxyalkyl ethers include acetoxymethoxy and 2,2- dimethylpropionyloxymethoxy. A selection of in vzvo-hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)- N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl. Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof which process (wherein R1, R2, R3, R4, R5, n, r and s are, unless otherwise specified, as defined in formula (I)) comprises of: a) reacting a ketone of formula (II):
(H) with an amine of formula (III):
(III); wherein Rb and Rc are R2 and R3 respectively, unless the value of R2 and/or R3 is hydrogen, in which case the appropriate Rb and/or Rc is a suitable amino protecting group such as those defined below; or b) reacting an amine of formula (IV):
(IV) with an aldehyde of formula (V):
(V) wherein Rb and Rc are as defined above; or c) reacting an aldehyde of formula (VI):
with an amine of formula:
R2 I HN^ ^R3
(VII) wherein Ra is R1 unless the value of R' is hydrogen, in which case Ra is a suitable amino protecting group such as those defined below; or d) if R1 is C,.6alkyl, reacting a compound of formula (VIII):
wherein Rb and Rc are as defined above, with a compound of formula (IX);
(IX) wherein K is hydrogen or C,.5alkyl; or e) reacting a compound of formula (X):
(X) wherein L is a suitable displaceable group, with an amine of formula (III); or f) reacting an amine of formula (IV) with a compound of formula (XI):
(XI) wherein L is a suitable displaceable group and Rb and Rc are as defined above; or g) reacting a compound of formula (XII):
wherein L is a suitable displaceable group, with an amine of formula (VII); or h) if R1 is not hydrogen, reacting a compound of formula (VIII) with a compound of formula (XIII):
R'-L (XIII) wherein L is a suitable displaceable group; or i) reducing a compound of formula (XIV):
or j) reducing a compound of formula (XV):
or k) if R1 is not hydrogen, reducing a compound of formula (XVI):
(XVI) wherein:
1) for preparing a compound wherein R1 is methyl, G is a suitable displaceable group; or
2) for preparing a compound wherein R1 is C2.6alkyl, G is C,.5alkyl; or and thereafter if necessary : i) converting a compound of the formula (I) into another compound of the formula (I); ii) removing any protecting groups; or iii) forming a pharmaceutically-acceptable salt or in vzvo-hydrolysable ester, amide or carbamate. L is a displaceable group, suitable values for L are for example, a halogeno or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4- sulphonyloxy group.
When G is a suitable displaceable group, suitable values for G are C^alkoxy, for example methoxy or ethoxy. Specific reaction conditions for the reactions a), b), c) and d), above, are as follows.
Ketones or aldehydes may be reacted with amines under standard reductive amination conditions. Imine formation may optionally be assisted with a Lewis acid for example titanium tetrachloride, in an inert solvent for example toluene. The reduction may occur for example in the presence of a reducing agent such as hydrogen and a hydrogenation catalyst (for example palladium on carbon), or zinc and hydrochloric acid, or sodium cyanoborohydride, or sodium triacetoxyborohydride, or sodium borohydride, iron pentacarbonyl and alcoholic potassium hydroxide, or borane and pyridine or formic acid. The reaction is preferable carried out in the presence of a suitable solvent such as an alcohol, for example methanol or ethanol, and at a temperature in the range of 0-50 °C, preferably at or near room temperature.
Compounds of formula (II), (III), (IV), (V), (VII) and (IX) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Compounds of formula (VI) may be prepared according to the following scheme:
Compounds of formula (VIII) may be prepared according to the following scheme:
Compounds of formula (VIA), (VIB) and (VIIIA) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art. Specific reaction conditions for the reactions e), f), g) and h), above are as follows: Amines and compounds with suitable leaving groups are reacted together under standard alkylation conditions. For example in the presence of a base, such as an inorganic base for example sodium carbonate or sodium hydroxide, or an organic base for example triethylamine, or in the presence of excess amine, in the presence of an inert solvent for example tetrahydrofuran or toluene and at a temperature in the range of 50-120 °C, preferably at or near reflux. Compounds of formula (X), (XI) and (XIII) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Compounds of formula (XII) may be prepared according to the following scheme.
(XΠA)
Compounds of formula (XIIA) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
Specific reaction conditions for the reactions i), j) and k), above, are as follows:
Compounds of formula (XIV), (XV) and (XVI) are reduced under standard reduction conditions for reducing an amide to an amine. For example, in the presence of a reducing agent such as borane, borane methyl sulphide complex, sodium borohydride or lithium aluminium hydride, in an inert solvent such as toluene or tetrahydrofuran, and at a temperature in the range of 0-120 °C, preferably at or near reflux.
Compounds of formula (XIV) may be prepared according to the following scheme:
(IV) +Cl
Compounds of formula (XV) may be prepared according to the following scheme:
(XVA) (XVB) wherein Ra, Rb and L are as hereinbefore defined.
Compounds of formula (XVI) may be prepared according to the following schemes:
(XVIA) Compounds of formula (XIV A) and (XVIA) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.
When an optically active form of a compound of the formula (I) is required, it may be obtained, for example, by carrying out one of the aforesaid procedures using an optically active starting material or by resolution of a racemic form of said compound using a conventional procedure.
An example of converting one compound of formula (I) into another compound of formula (I) is the conversion of R1, R2 or R3 when they are hydrogen to a different R1, R2, or R3. For example an alkyl group could be introduced by standard alkylation or reductive amination techniques, such as those described above.
It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Greene, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.
A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon. A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
In order to use a compound of the formula (I) or a pharmaceutically-acceptable salt or in vzvo-hydrolysable ester, amide or carbamate thereof for the therapeutic treatment (including prophylactic treatment) of mammals including humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition. The pharmaceutical compositions of compounds of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, topical, parenteral, buccal, nasal, vaginal or rectal administration or by inhalation. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions. A preferred route of administration is intravenously in sterile isotonic solution.
In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to hereinabove.
The pharmaceutical compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.05 to 75 mg/kg body weight (and preferably of 0.1 to 30 mg/kg body weight) is received. This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease condition being treated according to principles known in the art.
Typically unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.
According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I) as defined hereinbefore or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof, in association with a pharmaceutically-acceptable excipient or carrier.
According to a further aspect of the present invention there is provided a compound of the formula (I) or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.
A further feature of the present invention is a compound of formula (I) and pharmaceutically-acceptable salts or an in vzvo-hydrolysable ester, amide or carbamate thereof, for use as a medicament to inhibit the [3H]-emopamil binding site in a warm-blooded animal such as a human being.
Thus according to a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof, in the manufacture of a medicament for use in the inhibition of the [3H]-emopamil binding site in a warm-blooded animal such as a human being.
According to a further feature of the invention there is provided a method of inhibiting of the [3H]-emopamil binding site in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically-acceptable salt or an in vivo- hydrolysable ester, amide or carbamate thereof, as defined hereinbefore.
The following Biological Test Methods, Data and Examples serve to illustrate the present invention. Biological Test Methods -H-Emopamil binding to guinea pig liver membranes The method of (-)-3H-emopamil binding was a modification of Zech, C, Staudinger
R., Mϋhlbacher, J. and Glossmann, H. Novel sites for phenylalkylamines: characterisation of a sodium-sensitive drug receptor with (-)-3H-emopamil. Eur. J. Pharm. 208: 119-130, 1991. The reaction mixture contained: Assay buffer: 10 mM Tris-HCl, 0.1 mM phenylmethylsulphonyl fluoride (PMSF), 0.2% bovine serum albumin (BSA), pH 7.4 at 4 °C.
Radioligand: 0.96 nM (-)-3H-emopamil (Amersham). Guinea pig liver membranes: 40mg/mL original wet weight. Compounds: 1-300 nM. Total volume: 500 μL.
This mixture was incubated for 60 minutes at 37 °C. The incubation was terminated by filtering with a Brandel Cell Harvester over Whatman GF/C filters that had been soaked for at least 120 minutes in 0.3% polyethylenimine (PEI) and washed three times with 5 mL of wash buffer containing 10 mM Tris-HCl, 10 mM MgCl2, 0.2% BSA, pH 7.4 at 25 °C.
Specific binding was defined with 10 μM emopamil. In general compounds with an IC50 below 300nM in this test were of interest. Guinea-pig liver membrane preparation:
Male guinea pigs were sacrificed by CO2 asphyxiation with dry ice. The livers were quickly excised and weighed and rinsed in membrane preparation buffer containing 10 mM
Hepes, 1 mM Tris base-EDTA, 250 mM sucrose, pH 7.4. The livers were then minced, homogenised in 10 times volume with a motor driven Teflon-glass homogeniser with three strokes on ice. The homogenate was centrifuged at 1000 x g in a SS34 rotor for 5 minutes at 4
°C. The supernatant was filtered through 4 layers of gauze and then centrifuged at 8000 x g for 10 minutes at 4°C. This resulting supernatant was centrifuged at 40,000 x g for 15 minutes at 4 °C. The resulting pellet was resuspended in assay buffer and centrifuged again at 40,000 x g for 15 minutes at 4 °C. This pellet was resuspended in assay buffer (2.5 fold with respect to original wet weight) and homogenised with one stroke with the Teflon-glass homogeniser.
Aliquots of 1 mL were stored at -70 °C.
-H-D-888 binding to rat brain cortical membranes
The method of 3H-D-888 binding was a modification of Reynolds, I.J., Snowman,
A.M. and Synder, S.H. (-)-[3H] Desmethoxyverapamil labels multiple calcium channel modular receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines. J. Pharmacol. Exp. Ther. 237: no.3, 731-738, 1986.
The assay tubes contained the following: assay buffer: 50 mM Hepes, 0.2% BSA, pH 7.4 radioligand: lηM 3H-D888 (Amersham) rat cortical membranes: 6 mg/mL original wet weight compounds: 0.3-100 μM Total volume: 1000 μL.
This mixture was incubated for 60 minutes at 25 °C. The assay was terminated by filtering with a Brandel Cell Harvester over Whatman GF/C filters that had been soaked for at least 120 minutes in 0.3% polyefhylenamine (PEI) and washed three times with 5 mL of wash buffer containing 20 mM Hepes, 20 mM MgCl2, pH 7.4. Specific binding was measured with 10 μM methoxyverapamil (D-600). This assay was used to determine in vitro selectivity of compounds vs. L-type voltage sensitive calcium channels, i.e. high affinity for the 3H-D888 binding site would show a lack of selectivity. Rat brain cortical membrane preparation Male Sprague-Dawley Rats were sacrificed by decapitation and the brains were quickly excised. The cerebellum and brain stem were removed and discarded; and the rest of the brain was rinsed in 320 mM sucrose. The brain was then homogenised in a 10-fold volume of 320 mM sucrose with a motor driven Teflon-glass homogeniser using 10 strokes on ice. The homogenate was spun at 1000 x g for 10 minutes at 4 °C in a SS-34 rotor. The supernatant was then spun at 29,000 x g for 20 minutes. The resulting pellet was resuspended in membrane buffer (5 mM Hepes, 0.2% BSA, pH 7.4) to a final concentration of 60 mg original wet weight/mL. Gerbil Global Model of Cerebral Ischaemia
Male Mongolian gerbils (Charles River) weighing 60-70 grams are used in these experiments. They are housed in individual cages with food (Purina Rodent Chow) and water available ad libitum. The animal room is maintained at 23 ± 2 °C, and is on an automatic 12 hour light cycle.
The gerbils are brought to the surgical suite and dosed intraperitoneally with the test agent or vehicle, forty five minutes prior to surgery. Drugs are administered at a volume of 5 mL/kg (intraperitoneal). Vehicle is generally saline, with sodium phosphate added to adjust pH, if needed. Forty-five minutes after dosing the gerbils are anaesthetised with halothane (3.3%) which is delivered along with oxygen (1.5 1/M) through a face mask. After the gerbils are anaesthetised, halothane is continued at a maintenance level of 1.5-2 % along with oxygen. The ventral surface of the neck is shaved and cleaned with alcohol. Surgical procedures are carried out on a thermostat-controlled heating pad set to 37 °C. An incision is made in the neck, the carotid arteries are dissected away from the surrounding tissue, and isolated with a 5 cm length of Silastic tubing. When both arteries have been isolated they are clamped with microaneurysm clips (Roboz Instruments). The arteries are visually inspected to determine that the blood flow has been stopped. After 5 minutes the clips are gently removed from the arteries and blood flow begins again. A sham control group is treated identically but is not subjected to carotid artery occlusion. The incisions are closed with suture and the gerbils removed from the anaesthesia masks and placed on another heating pad to recover from the anaesthesia. When they have regained the righting reflex and are beginning to walk around, they are again dosed with the test compound and returned to their home cages. This occurs approximately five minutes after the end of surgery.
Twenty-four hours post ischaemia gerbils are tested for spontaneous locomotor activity, using a Photobeam Activity System from San Diego Instruments. They are individually placed in Plexiglas chambers measuring 27.5 cm x 27.5 cm x 15 cm deep. The chambers are surrounded by photocells, and every time a beam is broken one count is recorded. Each gerbil is tested for two hours, and cumulative counts are recorded at 30, 60, 90, and 120 minutes. Mean counts are recorded for each group and drug groups are compared to control with an ANOVA and Bonferroni post test. After each gerbil is tested it is returned to its home cage. At this time gerbils are also observed for any changes from normal behaviour.
For the next two days no specific testing is performed, but the gerbils are observed two to three times per day for any unusual behaviours or obvious neurological symptoms (i.e. ataxia, convulsions, stereotypic behaviour). Four days post ischaemia the gerbils are sacrificed by decapitation and their brains removed and preserved in 10% buffered formalin. Brains were removed, fixed and stained with hematoxylin and eosin. Under a light microscope, hippocampal fields were observed and graded for damage to the CA1 subfield: 0 to 4 scale, with 0 representing no damage and 4 representing extensive damage. Transient focal ischaemia in rats
The method was as described by Lin, T-N., He, Y.Y., Wu, G., Khan, M. And Hsu, CN. Effect of brain edema on infarct volume in a focal model cerebral ischaemia model in rats. Stroke 24:117-121, 1993, which model is considered to be relevant to the clinical situation. Male Long-Evans rats 250-350 g were used. Surgery leading to focal ischaemia was conducted under anaesthesia with 100 mg/kg ketamine and 5 mg/kg i.m. xylazine. Rectal temperature was monitored and maintained at 37.0 + 0.5 °C. The right middle cerebral artery (MCA) was exposed using microsurgical techniques. The MCA trunk was ligated immediately above the rhinal fissure with 10-0 suture. Complete interruption of blood flow was confirmed under an operating microscope. Both common carotid arteries were then occluded using nontraumatic aneurysm clips. After a predetermined duration of ischaemia (45 min), blood flow was restored in all three arteries. Twenty-four hours post occlusion, rats were killed under ketamine anaesthesia by intracardiac perfusion with 200 mL of 0.9% NaCl. The brain was removed and processed with 2% triphenyltetrazolium chloride to identify and quantitate the infarcted brain region. Compounds were administered by intravenous infusion for 4 hours. Data
The following results were obtained in the 3H-Emopamil binding to guinea pig liver membranes test.
Examples
The invention is now illustrated but not limited by the following Examples in which unless otherwise stated:-
(i) concentrations were carried out by rotary evaporation in vacuo;
(ii) operations were carried out at ambient temperature, that is in the range 18-26 °C and under a nitrogen atmosphere otherwise stated;
(iii) column chromatography (by the flash procedure) was performed on Merck Kieselgel silica (Art. 9385) unless otherwise stated;
(iv) yields are given for illustration only and are not necessarily the maximum attainable;
(v) the structure of the end-products of the formula I were generally confirmed by NMR and mass spectral techniques - proton magnetic resonance spectra were determined in DMSO- δ6 unless otherwise stated using a Varian Gemini 2000 spectrometer operating at a field strength of 300 MHz; chemical shifts are reported in parts per million downfield from tetramethylsilane as an internal standard (δ scale) and peak multiplicities are shown thus: s, singlet; bs, broad singlet; d, doublet; AB or dd, doublet of doublets; t, triplet, dt, double of triplets, m, multiplet; bm, broad multiplet and unless otherwise stated Η NMR is quoted; fast- atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected, in this application, (M+H)+ is quoted unless otherwise stated;
(vi) intermediates were not generally fully characterized and purity was in general assessed mass spectral (MS) or NMR analysis; and
(vii) in which the following abbreviations (also used hereinabove) may be used :-
DMSO is dimethylsulphoxide; CDC13 is deuterated chloroform; m/s is mass spectroscopy;
THF is tetrahydrofuran;
DCM is dichloromethane;
Com Av is commercially available; and SM is starting material.
Example 1 4-r2-(Piperidin-l-yl ethyl(N-methyl)amino1thiochroman
To a solution of 4-[2-(piperidin-l-yl)ethylamino]thiochroman (Reference Example 1) (1.27 g, 4.59 mmol) in 46 mL of THF was added triethylamine (1.34 mL, 9.64 mmol), followed by ethyl chloroformate (485 μL, 5.05 mmol). A white precipitate was formed immediately. The reaction was stirred at room temperature for lh. Solvents were then removed in vacuo. The residue was taken up in water (50 mL) and ether (50 mL). The aqueous layer was extracted with ether (2 x 50 mL). The combined organic layers were washed with saturated ΝaHCO3 solution (1 x 50 mL), water (1 x 50 mL) and brine (1 x 50 mL) and dried over MgSO4. Removal of solvents yielded a light yellow liquid. The yellow liquid was dissolved in 32 mL of THF and lithium aluminium hydride (749 mg, 19.7 mmol) was added in small portions. After addition was complete, the reaction was heated to reflux. After 2h, the reaction was cooled and quenched with Na2SO4.10H2O. The mixture was stirred until all the solids had turned white. It was then filtered through a small pad of Celite. Solvents were removed to afford a yellow liquid. Purification by silica gel chromatography (20:1 DCM/2M ammonia in methanol) yielded the title compound as a yellow liquid (1.15 g, 86%). NMR (CDClj): 1.43 (m, 2H), 1.57 (m, 4H), 2.27-2.06 (m, 2H), 2.28 (s, 3H), 2.71-2.33 (m, 8H), 3.08 (m, 2H), 3.77 (dd, IH), 7.05 (m, 3H), 7.59 (d, IH); m/s: 291. Example 2
4-[2-(moφholino)ethyl(N-methy0amino]thiocIιroman Formaldehyde (37 wt% in H2O, 3.5 mL, 46.8 mmol) was added to a solution of 4-[2-
(moφholino)ethylamino]thiochroman (Reference Example 2) (500 mg, 1.80 mmol) in methanol (11 mL) and the reaction was stirred for lh at room temperature. The reaction was then cooled in an ice bath and sodium borohydride (611 mg, 16.2 mmol) was added slowly. When addition was complete, the ice bath was removed and the reaction was allowed to stir at room temperature overnight. Solvents were then removed in vacuo. The residue was taken up in water (30 mL) and DCM (30 mL). The aqueous layer was extracted with DCM (2 x 30 mL). The combined organic layers were washed with brine (1 x 50 mL) and dried over MgSO4. Solvents were removed in vacuo to yield a yellow liquid. Purification by silica gel chromatography (25: 1 DCM/2M ammonia in methanol) afforded the title compound as a yellow liquid (379 mg, 72%). ΝMR (CDC13): 2.09 (m, IH), 2.22 (m, IH), 2.30 (s, 3H), 2.60- 2.42 (m, 7H), 2.65 (m, IH), 3.08 (m, 2H), 3.70 (m, 4H), 3.77 (dd, IH), 7.05 (m, 3H), 7.58 (m,lH); m/s: 293. Example 3 4-[2-(Piperidin- 1 -yl)ethyl(N-ethyl amino]thiochroman A solution of 4-[2-(piperidin-l-yl)ethyl(N-acetyl)amino]thiochroman (Method 1)
(360 mg, 1.13 mmol) in 15 mL of THF was cooled to 0 °C and borane-methyl sulfide complex (2.0M in toluene, 1.4 mL, 2.8 mmol) was added. The reaction mixture was then heated to reflux. After 3h, the reaction was cooled and 3 mL of methanol was added. 1M aqueous HC1 (15 mL) was added and the reaction was heated to reflux for lh. The reaction was then cooled and the pH was adjusted to 14 with 1M ΝaOH solution. The layers were separated and the aqueous layer was extracted with ether (3 x 30 mL). The combined organic layers were dried over MgSO4. Solvents were removed to yield a yellow liquid. Purification by silica gel chromatography (20:1 DCM:2M ammonia in methanol) afforded a yellow liquid (263 mg, 76%). ΝMR (CDC13): 1.04 (t, 3H), 1.42 (m, 2H), 1.55 (m, 4H), 2.00 (m, IH), 2.60- 2.28 (m, 10H), 2.70 (m, IH), 3.07 (m, 2H), 3.90 (dd, IH), 7.06 (m, 3H), 7.70 (m, IH); m/s: 305. Example 4
4- 2-(morpholino)ethyl(N-allyl)aminolthiochroman
To a solution of 4-[2-(moφholino)ethylamino]thiochroman (Reference Example 2) (500 mg, 1.80 mmol) in 3.6 mL of THF was added allyl bromide (311 μl, 3.59 mmol), followed by triethylamine (501 μl, 3.59 mmol) and the reaction was heated to reflux for 17h. A yellow precipitate had formed and the reaction was cooled. Purification by silica gel chromatography (20:1 DCM:2M ammonia in methanol) afforded the title compound as a yellow liquid (143 mg, 25%). ΝMR (CDC13): 1.96 (m, IH), 2.60-2.25 (m, 8H), 2.70 (m, IH), 3.05 (m, 3H), 3.25 (m, IH), 3.68 (t, 4H), 3.95 (dd, IH), 5.09 (d, IH), 5.21 (dd, IH), 5.82 (m, IH), 7.06 (m, 3H), 7.71 (m, IH); m/s: 319. Example 5 (-')-4- 2-(1.2,3.4-tetrahvdroisoquinolin-2-yl')ethylamino1thiochroman
To a suspension of (-)-4-[2-(l,2,3,4-tetrahydroisoquinolin-2-yl)acetamido] thiochroman (Method 3) (868 mg, 2.56 mmol) in 17 mL of THF was added lithium aluminium hydride (389 mg, 10.3 mmol) and the reaction was heated to reflux. After 23h, the reaction was cooled and Νa2SO4.10H2O was added to quench the reaction. The suspension was then stirred overnight until all the salts had turned white. The mixture was then filtered through MgSO4 and solvents were removed to yield a yellow liquid. Purification by silica gel chromatography (20:1 DCM:2M ammonia in methanol) yielded the title compound as a yellow liquid (756 mg, 90%). NMR (CDC13): 1.95 (m, IH), 2.33 (m, IH), 2.67 (m, 4H), 2.86 (m, 5H), 3.34 (td, IH), 3.60 (s, 2H), 3.79 (m, IH), 7.01 (m, 2H), 7.11 (m, 6H); m/s: 325; [a]D = -83° (c = 0.0066, MeOH).
Examples 6-19
Using an analogous procedure to that described in Examples 1 -5 and Reference Example 1 (see below), the following compounds were prepared.
* Free
1 Calc'd for C17H20N2S:C, 71.79; H, 7.09; N, 9.85, Found: C, 71.52; H, 7.06; N, 9.52.
2 (+)-enantiomer; [a]D= +100° (c=0.0062, MeOH). (+)-enantiomer;[a]D= +10° (c=0.01, MeOH).
4 (-)-enantiomer;[a]D= -9° (c=0.01, MeOH). NMR (CDC13) results:
Example 6: 4-(3-Mθφholin-4-ylpropylamino)thiochroman, 1.68 (m, 2H), 1.93 (m, IH), 2.40 (m, 7H), 2.70 (m, 2H), 2.87 (dt, IH), 3.34 (td, IH), 3.68 (t, 4H), 3.74 (m, IH), 7.20-6.99 (m, 4H). Example 7: 4-(2-Dimethylaminoethylamino)thiochroman, 2.00-1.94 (m, 2H), 2.21 (s, 6H),
2.48-2.31 (m, 3H), 2.87-2.71 (m, 3H), 3.37 (m, IH), 3.76 (m, IH), 7.18-6.99 (m, 4H).
Example 8: 4-(2-Isopropylaminoethylamino)thiochroman, 1.06 (d, 6H), 1.76 (br s, 2H), 1.93
(m, IH), 2.32 (m, IH), 2.89-2.66 (m, 6H), 3.35 (td, IH), 3.77 (m, IH), 7.19-6.96 (m, 4H). Example 9: 4-((2-Pyrrolidin-l-ylethyl)amino)thiochroman, 1.60 (br s, IH), 1.75 (m, 4H),
1.94 (m, IH), 2.33 (m, IH), 2.46 (m, 4H), 2.87-2.55 (m, 5H), 3.36 (td, IH), 3.77 (t, IH), 7.13-
6.97 (m, 3H), 7.16 (d, IH).
Example 10: 4-(2-Diethylaminoethylamino)thiochroman, 0.98 (t, 6H), 1.95 (m, IH), 2.31 (m,
IH), 2.52 (q, 4H), 2.55 (t, 2H), 2.71 (m, 2H), 2.86 (dt, IH), 3.36 (td, IH), 3.75 (dd, IH), 7.18- 6.97 (m, 4H).
Example 1 1 : 4-((3-Piperidin-l-ylpropyl)amino)thiochroman, 1.80-1.30 (m, 9H), 1.92 (m,
IH), 2.32 (m, 6H), 2.68 (m, 2H), 2.85 (m, IH), 3.35 (td, IH), 3.74 (m, IH), 7.20-6.98 (m,
4H).
Example 12: 4-((3-(4-Methylpiperazin-l-yl)propyl)amino)thiochroman, 1.69 (m, 2H), 1.92 (m, IH), 2.27 (s, 3H), 2.42 (m, 1 IH), 2.72 (m, 2H), 2.86 (dt, IH), 3.34 (td, IH), 3.73 (t, IH),
7.18-6.97 (m, 4H).
Example 13: 4-(2-Phenylaminoethylamino)thiochroman, 1.55 (br s, IH), 1.97 (m, IH), 2.31
(m, IH), 2.97-2.84 (m, 3H), 3.23 (m, 2H), 3.33 (m, IH), 3.79 (m, IH), 4.14 (br s, IH), 6.74-
6.59 (m, 3H), 7.21-7.00 (m, 6H). Example 14: 4-(2-Benzylaminoethylamino)thiochroman, 1.52 (br s, 2H), 1.94 (m, IH), 2.30
(m, IH), 2.88-2.73 (m, 5H), 3.34 (td, IH), 3.74 (t, IH), 3.77 (s, 2H), 7.35-6.98 (m, 9H).
Example 15: 4-(Methyl-(3-(4-methylpiperazin-l-yl)propyl)amino)thiochroman, 1.68 (m, 2H),
2.12 (m, 2H), 2.22 (s, 3H), 2.29 (s, 3H), 2.58-2.34 (m, 12H), 3.07 (m, 2H), 3.75 (dd, IH),
7.08-6.99 (m, 3H), 7.55 (m, IH). Example 16: 4-(Ethyl-(2-moφholin-4-yl-ethyl)amino)thiochroman, 1.05 (t, 3H), 2.02 (m,
IH), 2.28 (m, IH), 2.68-2.41 (m, 10H), 3.06 (m, 2H), 3.68 (t, 4H), 3.91 (dd, IH), 7.06 (m,
3H), 7.70 (m, IH).
Example 17: (R)-4-(2-(3,4-Dihydro-lH-isoquinolin-2-yl)ethyl)amino)thiochroman, 1.95 (m,
1Η), 2.33 (m, 1Η), 2.69 (m, 4Η), 2.85 (m, 5H), 3.34 (td, IH), 3.60 (s, 2H), 3.79 (m, IH), 6.99 (m, 2H), 7.11 (m, 6H). Example 18: (S)-4-(N'-(2-(3,4-Dihydro-lH-isoquinolin-2-yl)-N-ethyl)amino)thiochroman, 2.12 (m, 1Η), 2.24 (m, 1Η), 2.32 (s, 3Η), 2.73 (m, 6H), 2.89 (t, 2H), 3.10 (dd, 2H), 3.62 (s, 2H), 3.81 (dd, IH), 7.15-6.97 (m, 7H), 7.62 (m, IH).
Example 19: (R)-4-(N'-(2-(3,4-Dihydro-lH-isoquinolin-2-yl)-N-ethyl)amino)thiochroman, 2.12 (m, 1Η), 2.26 (m, 1Η), 2.33 (s, 3Η), 2.81-2.64 (m, 6H), 2.89 (t, 2H), 3.08 (t, 2H), 3.62 (s, 2H), 3.81 (dd, IH), 7.12-6.97 (m, 7H), 7.60 (d, IH). Examples 20-25
Using an procedure analogous to that described in Example 5 compounds of Examples 20, 21, 23, 24 and 25 were prepared. Example 22 was prepared by the method of Example 1.
S Enantiomer SM - starting material ΝMR (DMSO) results: Example 20: (5)-4-(N-2-(N -Benzyl-N-methylamino)ethyl(N-methyl)amino)thiochroman, 1.84-2.00 (m, IH), 2.06-2.20 (m, 7H), 2.40-2.60 (m, 4H), 3.01-3.11 (m, 2H), 3.46 (s, 2H), 3.70-3.79 (m, IH), 6.96-7.13 (m, 3H), 7.19-7.35 (m, 5H), 7.54 (d, IH). Example 21 : (S)-4-(N'-Methyl-N'-(2-pyrrolidin-l-ylethyl)amino)thiochroman, 1.59-1.69 (m,
4H), 1.86-2.01 (m, IH), 2.05-2.23 (m, 4H), 2.35-2.60 (m, 8H), 3.02-3.13 (m, 2H), 3.70-3.80
(m, IH), 6.97-7.12 (m, 3H), 7.53-7.61 (m, IH).
Example 22: (S)-4-(N'-(2-(l,3-Dihydroisoindol-2-yl)ethyl)-N'-methylamino)thiochroman, 1.88-2.05 (m, IH), 2.10-2.29 (m, 4H), 2.53-2.67 (m, 2H), 2.71-2.90 (m, 2H), 3.03-3.13 (m,
2H), 3.75-3.90 (m, 5H), 6.96-7.26 (m, 7H), 7.58 (d, IH).
Example 23 : (5)-4-(N'-(2-(l,3-Dihydroisoindol-2-yl)ethyl)amino)thiochroman, 1.72-1.93 (m,
2H), 2.20-2.31 (m, IH), 2.63-2.91 (m, 5H), 3.22-3.38 (m, IH), 3.72-3.79 (m, IH), 3.84 (s,
4H), 6.95-7.32 (m, 8H). Example 24: (5)-4-((2-Azepan-l-ylethyl)amino)thiochroman, 1.37-1.67 (m, 8H), 1.67-1.92
(m, 2H), 2.15-2.31 (m, IH), 2.31-2.73 (m, 8H), 2.77-2.90 (m, IH), 3.20-3.48 (m, IH), 3.69
(m, IH), 6.93-7.30 (m, 4H).
Example 25: (S)-4-(2-(N'-Benzyl-N-methylamino)ethylamino)thiochroman, 1.70-1.85 (m,
2H), 2.09 (s, 3H), 2.16-2.30 (m, IH), 2.40-2.55 (m, 2H), 2.58-2.89 (m, 3H), 3.20-3.53 (m, 3H), 3.65-3.73 (m, IH), 6.96-7.36 (m, 9H).
Example 26
4-[2-f Piperidin- 1 -yl ethyl(N-methyl amino"|thiochroman bismaleate salt
A solution of 4-[2-(piperidin-l-yl)ethyl(N-methyl)amino]thiochroman (Example 1)
(1.15 g, 3.96 mmol) in 10 mL of ether was added to a solution of maleic acid (965 mg, 8.31 mmol) in 80 mL of ether. The mixture was stirred for 30 min and then allowed to stand. After several days, a white solid had formed. This was triturated with ether and then filtered and dried to yield the bismaleate (1.77 g, 85%). ΝMR: 1.51 (m, 2H), 1.70 (m, 4H), 2.09 (m, 2H),
2.20 (s, 3H), 2.70 (m, IH), 2.85 (m, IH), 3.29-3.08 (m, 8H), 3.83 (t, IH), 6.15 (s, 4H), 7.09
(m, 3H), 7.52 (d, lH). m/s: 291. Examples 27 and 28
Using the procedure of Example 26, salts of the Examples were prepared. The following bismaleate salts are provided by way of illustration:
1 (-) enantiomer; [a]D = -17° (c=0.01, MeOH) NMR results:
Example 27: 2.07 (m, IH), 2.58 (m, 5H), 2.69 (m, 2H), 3.35-3.00 (m, 4H), 3.64 (m, 4H), 4.48 (m, 1 H), 6.13 (s, 4H), 7.32-7.14 (m, 3H), 7.44 (m, 1 H).
Example 28: 2.09 (m, 2H), 2.24 (s, 3H), 2.78 (m, IH), 3.17-2.93 (m, 6H), 3.29 (m, IH), 3.41 (m, 2H), 3.89 (t, IH), 4.36 (s, 2H), 6.14 (s, 4H), 7.11 (m, 4H), 7.25 (m, 3H), 7.54 (d, IH). REFERENCE EXAMPLES Reference Example 1 4- |"2-(Piperidin- 1 -vDethylamino"|thiochroman
To a solution of thiochroman-4-one (4.15 g, 25.3 mmol) in toluene (70 mL) at 0 °C was added 1 -(2-aminoethyl)piperidine (20 g, 156 mmol), followed by dropwise addition of titanium(IV) tetrachloride (1.0 M in toluene, 12 mL, 12 mmol). The addition of titanium(IV) tetrachloride was kept at a rate such that the temperature of the reaction mixture was kept below 10 °C. When addition was complete, the reaction was allowed to warm to room temperature. After 5h, the reaction mixture was filtered through Celite, rinsing the residue with toluene. Solvents were then removed in vacuo to yield a yellow liquid. The yellow liquid was then taken up in methanol (50 mL) and sodium borohydride (960 mg, 25.3 mmol) was added in small portions over 5 min. The reaction was then stirred at room temperature for 45 min. It was then added to water (75 mL) and ether (75 mL). The layers were separated and the aqueous layer was extracted with ether (2 x 50 mL). The combined organic layers were then washed with brine (1 x 100 mL) and dried over MgSO4. Solvents were removed in vacuo to yield a yellow liquid. Purification with silica gel chromatography (20:1 DCM:methanol, 1%
NH4OH) yielded the title compound as a yellow liquid (4.27 g, 61%). NMR (CDC13): 1.44 (m,
2H), 1.56 (m, 4H), 2.29-1.86 (m, 2H), 2.35 (m, 4H), 2.46 (m, 2H), 2.75 (m, 2H), 2.86 (dt,
IH), 3.36 (td, IH), 3.76 (t, IH), 7.19-6.99 (m, 4H); m/s: 277.
Reference Example 2
Using an analogous procedure to that described in Reference Example 1 , the following compound was prepared.
NMR (CDClj) Results: 1.96 (m, IH), 2.62-2.24 (m, 7H), 2.76 (m, 2H), 2.90 (m, IH), 3.35 (td, IH), 3.66 (m, 4H), 3.78 (m, IH), 7.16-7.00 (m, 4H) Preparation of Starting Materials
The starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of the starting materials used in the above reactions. Method 1 4-|"2-(Piperidin- 1 -vDethvKN-acetvDaminolthiochroman
To a solution of 4-[2-(piperidin-l-yl)ethylamino]thiochroman (Reference Example 1) (500 mg, 1.81 mmol) in 18 mL of DCM was added triethylamine (279 μL, 2.00 mmol), followed by acetyl chloride (142 μL, 2.00 mmol). The reaction was then stirred at room temperature. After 5h, the reaction was added to water (20 mL) and extracted with ether (2 x 20 mL). The combined organic layers were dried over Νa2SO4. Solvents were removed to yield a colorless liquid. Purification by silica gel chromatography (20:1 DCM:2 M ammonia in methanol) afforded the title compound (490 mg, 85%). NMR: 1.35 (m, 6H), 2.05 (s, 1.5H), 2.13 (s, 1.5H), 2.14 (m, 8H), 3.36-2.70 (m, 4H), 5.05 (dd, 0.5H), 5.29 (m, 0.5H), 7.15-7.00 (m, 4H); m/s: 319. Method 2 4-[2-(Moφholino)ethyl(N-acetyl)amino1thiochroman
To a solution of 4-[2-(moφholino)ethylamino]thiochroman (Reference Example 2) (500 mg, 1.80 mmol) in 18 mL of DCM added acetyl chloride (141 μl, 1.98 mmol) followed by triethylamine (276 μl, 1.98 mmol) and the reaction was stirred overnight. The reaction was then added to saturated ΝH4C1 solution (30 mL) and ether (30 mL). The aqueous layer was extracted with ether (2 x 30 mL) and the combined organic layers were washed with water (1 x 30 mL) and brine (1 x 30 mL) and dried over MgSO4. Solvents were removed to yield a yellow liquid. Purification by silica gel chromatography (20:1 DCM:2 M ammonia in methanol) afforded the free base of the title compound as a yellow liquid (505 mg, 87%). The yellow liquid (200 mg, 0.624 mmol) was taken up in 5 mL of ether and maleic acid (87 mg, 0.749 mmol) in 8 mL of ether was added. A white precipitate was formed initially which settled down to a yellow oil. After 3 days of standing, the yellow oil had solidified to a light yellow solid - 4-[2-(moφholino)ethyl(N-acetyl)amino]thiochroman maleate salt - which was collected by filtration and dried under vacuum. ΝMR: 2.51-2.16 (m, 5H), 3.90-2.63 (m, 14H), 5.15 (m, IH), 6.10 (s, 2H), 7.20-6.94 (m, 4H); m/s: 321. Method 3
(-)-4- 2-(1.2,3.4-tetrahydroisoquinolin-2-yl)acetamido]thiochroman
To a solution of (-)-4-[2-chloroacetamido]thiochroman (Method 5) (750 mg, 3.10 mmol) in 18 mL of acetonitrile was added 1,2,3,4-tetrahydroisoquinoline (1.2 mL, 9.3 mmol) and the reaction was heated to reflux for 4h. The reaction mixture was cooled and then added to DCM/ether (75 mL) and saturated ΝaHCO3 solution (25 mL). The organic layers were washed with brine (1 x 40 mL) and dried over Na2SO4. Removal of solvents gave a yellow solid which was triturated with ether. The light yellow solid was collected by filtration and dried under vacuum (904 mg, 86%). NMR (CDC13): 2.20 (m, IH), 2.35 (m, IH), 2.81 (m, 4H), 3.00 (m, 2H), 3.23 (s, 2H), 3.71 (s, 2H), 5.24 (m, IH), 7.24-6.97 (m, 7H), 7.50 (m, IH); m/s: 339; [a]D = -92° (c = 0.0088, MeOH). Method 4
(- -4-[2-chloroacetamidolthiochroman
To a solution of (-)-4-aminothiochroman (Method 5) (1.00 g, 6.05 mmol) and 2,6- lutidine (1.27 mL, 10.9 mmol) in 23 mL of DCM at 0 °C was added chloroacetyl chloride (770 μL, 9.68 mmol) dropwise. After 5h, the resulting yellow solution was added to water (20 mL) and DCM (20 mL). The aqueous layer was extracted again with DCM (1 x 20 mL). The combined organic layers were washed with 1M HC1 solution (1 x 50 mL), water (1 x 50 mL) and brine (1 x 50 mL) and dried over Na2SO4. Solvents were removed to yield a yellow solid which was triturated with ether to give the title compound as a white solid (850 mg, 58%). NMR (CDC13): 2.18 (m, IH), 2.40 (m, IH), 3.03 (m, 2H), 4.10 (s, 2H), 5.22 (m, IH), 6.77 (m, IH), 7.23-7.04 (m, 3H); [a]D= -150° (c = 0.0094, MeOH). Method 5 (+)-4-[2-chloroacetamido]thiochroman and (-)-4-aminothiochroman
To dimethoxyethane (700 mL) was added 4-aminothiochroman (78 gram, 0.473 mole), isopropylchloroacetate (40 gram, 0.293 mole) and CHIRAZYME L-2 lipase attached to carrier-2 (16 grams, obtained from Roche Diagnostics GmbH, Germany). The head space was flushed with nitrogen and the mixture gently stirred at room temperature for 5.5 hours. The enzyme was removed by filtering the reaction mixture through a Whatman 113 filter paper, the enzyme was then rinsed with dimethoxyethane (400 mL) and the filtrates combined and concentrated to 600 mL by evaporation under reduced pressure at a water bath temperature of 30 °C. To the concentrated dimethoxyethane solution was added 1 molar HC1 (1200 mL) over a period of 15 minutes resulting in the precipitation of the reaction product (+)-4-[2-chloroacetamido]thiochroman. The solid was resuspended in 1 molar HC1 (2000 mL), recovered by filtration, washed in water (2000 mL), recovered by filtration and dried under vacuum at room temperature. The yield of (+)-4-[2-chloroacetamido]thiochroman was 51 grams (0.21 moles, 90% yield of enantiomer). The filtrate from the HC1 precipitation step was stored at 4 °C for 16 hours during which time further precipitate of (+)-4-[2- chloroacetamidojthiochroman occurred, this was removed by filtration through a Whatman 113 filter paper and the clear filtrate adjusted to pH 12 with sodium hydroxide (40% w/v). The solution was then extracted with n-hexane (2 x 1000 mL) to recover unreacted (-)-4- aminothiochroman.The hexane was recovered, dried with anhydrous sodium sulphate and filtered. The hexane was then removed under vacuum initially at a water bath temperature of 30 °C and then finally by holding at 50 °C for 30 minutes yielding a cloudy, yellow/brown, semi-solid residue (25.7 grams). Kugelrohr distillation yielded a light yellow liquid, (-)-4- aminothiochroman, (bp 85-95 °C, 50-60 mTorr). [a]- -110° (c=0.49, MeOH). Enantiomeric purity of (+)-4-[2-chloroacetamido]thiochroman was determined directly by gas chromatography using the conditions outlined below. The amine was analysed under the same conditions after conversion to (-)-4-acetylaminothiochroman by treatment with acetic anhydride.
Column - Chrompak WCOT fused silica 25 m x 0.32 mm, coating CP Chirasil-Dex CB; Carrier - Helium; Temperature - 180 °C isothermal; Retention times - (-)-4- acetylaminothiochroman, 16 minutes and 17.2 minutes and (+)-4-[2- chloroacetamidojthiochroman, 25.9 minutes and 26.5 minutes. Method 6 (a) A suspension of N-(t-butoxycarbonyl)glycine (2.35, 1.34 x 10"2 mole) and 1- hydroxybenzotriazole (1.90 g, 1.41 x 10"2 mole) in DCM (50 mL) was treated with l-[3- dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (3.05 g, 1.59 x 10"2 mole) and triethylamine (2.3 mL, 1.65 x 10"2 mole), respectively. Immediately, a solution of (S)-4- aminothiochroman (2.18 g, 1.32 x 10"2 mole) in DCM (30 mL) was added. After stirring at ambient temperature for 23 hours, the reaction mixture was partitioned between water and DCM. The aqueous portion was extracted with additional DCM. The combined organic portions were washed (water, brine), dried, and evaporated to yellow oil which was purified by chromatography, eluting with 2:1 ethyl acetate :hexane (v:v), to give the product as a white foam (4.25 g, 99%). 'H ΝMR (DMSO): 1.38 (s, 9H), 1.92-2.17 (m, 2H), 2.96-3.14 (m, 2H), 3.44-3.63 (m, 2H), 4.93-5.06 (m, IH), 6.87-7.24 (m, 5H), 8.24 (d, IH). (b) A solution of the white foam from (a) (2.18 g, 6.76 x 10"3 mole) in THF (35 mL) was treated with concentrated hydrochloric acid (2 mL) and heated at 60 °C for two hours. The reaction mixture was partitioned between IN aqueous sodium hydroxide solution and DCM. The aqueous portion was extracted with additional DCM. The combined organic portions were washed (water, brine), dried, and evaporated to a white solid. The solid was dissolved in DCM and purified by chromatography, eluting with 10% 2.0 M ammonia in methanol:90% DCM (v/v), to give the product as a white solid (1.39 g, 93%). 'H ΝMR (DMSO): 1.91-2.27 (m, 4H), 2.97-3.20 (m, 4H), 4.96-5.07 (m, IH), 6.99-7.23 (m, 4H), 8.18 (d, IH). m/s: 223. (c) A suspension of the white solid from (b) (1.39 g, 6.25 x 10"3 mole) and sodium carbonate (1.98 g, 1.88 x 10'2 mole) in THF (32 mL) was treated with α,α' -dibromo-o-xylene (1.66 g, 6.29 x 10"3 mole) followed by refluxing for five hours. The reaction mixture was partitioned between water and DCM. The aqueous portion was extracted with additional DCM. The combined organic portions were washed (water, brine), dried, and evaporated to a white solid. The solid was dissolved in DCM/methanol and purified by chromatography, eluting with 5% 2.0 M ammonia in methanol:95% DCM (v/v), to give the product as a white solid (1.93 g, 95%). Η NMR (DMSO): 1.97-2.26 (m, 2H), 2.98-3.15 (m, 2H), 3.42 (s, 2H), 4.01 (s, 4H), 5.00-5.12 (m, IH), 7.01-7.29 (m, 8H), 8.34 (d, IH). m/s: 325.
Examples 29-33
Compounds of Examples 29-33 of the formula below were made by the procedure of Method 3, above.
NMR (DMSO) results:
Example 29: 2.03-2.27 (m, 5H), 2.50 (s, 1.2H), 2.75 (s, 1.8H), 2.94-3.06 (m, IH), 3.10-3.70 (m, 5H), 5.23-5.33 (m, 0.4H), 5.61-5.72 (m, 0.6H), 6.88-7.43 (m, 9H). Example 30: 1.59-1.77 (m, 4H), 2.05-2.34 (m, 2H), 2.43-2.61 (m, 5.2H), 2.75 (s, 1.8H), 2.95-
3.07 (m, IH), 3.20-3.46 (m, 3H), 5.33-5.42 (m, 0.4H), 5.59-5.70 (m, 0.6H), 6.88-7.18 (m,
4H).
Example 31 : NMR (CDC13): 2.19 (m, IH), 2.34 (m, IH), 2.81 (m, 4H), 2.98 (m, 2H), 3.23 (s, 2H), 3.66 (s, 2H), 5.24 (m, IH), 7.22-6.97 (m, 7H), 7.50 (m, IH); m/s: 339; [a]D= +91° (c =
0.0058, MeOH).
Example 32: 1.43-1.65 (s, 8H), 1.95-2.24 (m, 2H), 2.57-2.73 (m, 4H), 3.00-3.17 (m, 4H),
4.95-5.10 (m, IH), 7.00-7.22 (m, 4H), 7.96-8.09 (m, IH).
Example 33: 1.96-2.25 (m, 5H), 2.96-3.10 (m, 4H), 3.58 (s, 2H), 5.00-5.10 (m, IH), 6.95- 7.38 (m, 9H), 8.16-8.24 (m, IH).
Example 34
Following conventional procedures well known in the pharmaceutical art the following representative pharmaceutical dosage forms containing a compound of formula (I) can be prepared: (a) Tablet mg/tablet
Compound of Formula I 50.0
Mannitol, USP 223.75
Croscarmellose sodium 60
Maize starch 15.0
Hydroxypropylmethylcellulose (HPMC), USP 2.25
Magnesium stearate 3.0
(b) Capsule mg/capsule
Compound of Formula I 10.0
Mannitol, USP 488.5
Croscarmellose sodium 15.0
Magnesium stearate 1.5
(c) Injection
For intravenous administration, a compound of Formula (I) is dissolved in an isotonic sterile solution (5 mg/mL).

Claims

CLAIMS:
1. A method for treating neurological disorders comprising administration of a therapeutically-effective amount of any compound according to formula (I):
wherein:
R1 is hydrogen, C,.6alkyl, C2.6alkenyl or C2.6alkynyl;
R2 and R3 are independently selected from hydrogen, C,.6alkyl, C2.6alkenyl, C2_ 6alkynyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3.12cycloalkyl and C3_ 12cycloalkyl fused to a benzene ring, wherein said C,.6alkyl, C2.6alkenyl, C2.6alkynyl, are optionally substituted with one or more groups selected from halo, nitro, hydroxy, C,.6alkoxy, cyano, amino, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, mercapto, sulphamoyl, mesyl, N-C,_6alkylamino, N,N-(C,.6alkyl)2amino, C,.6alkoxycarbonyl, N-C,.6alkylcarbamoyl, N,N-(C].6alkyl)2carbamoyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3. 12cycloalkyl and C3.12cycloalkyl fused to a benzene ring; and wherein any aryl, heteroaryl, heterocycle, C3.12cycloalkyl and C3.!2cycloalkyl fused to a benzene ring may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,_6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N- (C,.6alkyl)amino, N,N-(C,.6alkyl)2amino, Cι.6alkanoylamino, N-(C,.6alkyl)carbamoyl, N,N-(C,_ 6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,.6alkoxycarbonyl, N-(C,_ 6alkyl)sulphamoyl, N,N-(C,.6alkyl)2sulphamoyl and phenylC ,.6alkyl; and a heterocycle or a heteroaryl ring containing an -ΝH- group may be optionally substituted on this nitrogen with C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C,.6alkylsulphonyl or phenylC ,.6alkyl; or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring and wherein said heterocyclic or heteroaryl ring is optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N- (C,.6alkyl)amino, NN-(C,.6alkyl)2amino, C,.6alkanoylamino, N-(C,.6alkyl)carbamoyl, N,N-(C,. 6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,.6alkoxycarbonyl, N-(C,.
6alkyl)sulphamoyl, NN-(C,.6alkyl)2sulphamoyl or phenylC, .6alkyl; and a heterocyclic or a heteroaryl ring containing an -ΝH- group is optionally substituted on this nitrogen with C,. 6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C^alkylsulphonyl;
R4 is selected from halo, hydroxy, C,.6alkyl, C^alkoxy, haloC,_6alkyl, cyano, nitro or C2.6alkenyl;
R5 is C,.6alkyl; n is 1 or 2; r is 0, 1, 2, 3 or 4, wherein at each occurrence the values of R4 may be the same or different; and s is 0, 1 , 2 or 3 wherein at each occurrence the values of R5 may be the same or different; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
2. The method according to Claim 1, for treating stroke, head trauma, transient cerebral ischaemic attack, and chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, diabetic neuropathy, amyotrophic lateral sclerosis, multiple sclerosis and AIDS-related dementia.
3. The method according to Claim 1, for treating neurological disorders treatable by inhibition of the [3H]-emopamil binding site.
4. A pharmaceutical composition comprising any compound according to formula (I), or a in vzvo-hydrolysable ester, amide or carbamate thereof, together with a pharmaceutically- acceptable carrier, wherein, in a compound of formula (I):
R! is hydrogen, C,.6alkyl, C2.6alkenyl or C2.6alkynyl;
R2 and R3 are independently selected from hydrogen, C,.6alkyl, C2.6alkenyl, C2. 6alkynyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3.12cycloalkyl and C3. I2cycloalkyl fused to a benzene ring, wherein said C,.6alkyl, C2.6alkenyl, C2.6alkynyl, are optionally substituted with one or more groups selected from halo, nitro, hydroxy, C,.6alkoxy, cyano, amino, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, mercapto, sulphamoyl, mesyl, N-C,.6alkylamino, N,N-(C,_6alkyl)2amino, C^alkoxy carbonyl, N-C,.6alkylcarbamoyl, N,N-(C,.6alkyl)2carbamoyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3_ 12cycloalkyl and C3.12cycloalkyl fused to a benzene ring; and wherein any aryl, heteroaryl, heterocycle, C3.12cycloalkyl and C3.]2cycloalkyl fused to a benzene ring may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N- (C,.6alkyl)amino, N,N-(C,.6alkyl)2amino, C,.6alkanoylamino, N-(C,.6alkyl)carbamoyl, N,N-(C,. 6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C].6alkoxycarbonyl, N-(C,_ 6alkyl)sulphamoyl, N,N-(C,.6alkyl)2sulphamoyl and phenylC,.6alkyl; and a heterocycle or a heteroaryl ring containing an -ΝH- group may be optionally substituted on this nitrogen with C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C,.6alkylsulphonyl or phenylC^alkyl; or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring and wherein said heterocyclic or heteroaryl ring is optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N- (C,.6alkyl)amino, N,N-(C,.6alkyl)2amino, C,.6alkanoylamino, N-(C,.6alkyl)carbamoyl, NN-(C,. 6alkyl)2carbamoyl, C,_6alkylS(O)a wherein a is 0, 1 or 2, C,.6alkoxycarbonyl, N-(C,. 6alkyl)sulphamoyl, N,N-(C,.6alkyl)2sulphamoyl or phenylC,.6alkyl; and a heterocyclic or a heteroaryl ring containing an -ΝH- group is optionally substituted on this nitrogen with C,. 6alkyl, C2.6alkenyl, C2.5alkynyl, C,.5alkanoyl, C,.6alkylsulphonyl;
R4 is selected from halo, hydroxy, C,.6alkyl, C,_6alkoxy, haloC,.6alkyl, cyano, nitro or C2.6alkenyl;
R5 is C,.6alkyl; n is 1 or 2; r is 0, 1, 2, 3 or 4, wherein at each occurrence the values of R4 may be the same or different; and s is 0, 1 , 2 or 3 wherein at each occurrence the values of R5 may be the same or different.
5. A pharmaceutical composition according to Claim 4, comprising any compound in accord with formula (I), wherein: R1 is hydrogen, C,.6alkyl or C2.6alkenyl;
R2 and R3 are independently selected from hydrogen, aryl and C,.6alkyl optionally substituted with aryl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring wherein a heterocyclic ring containing an - ΝH- group may be optionally substituted on this nitrogen with C,.6alkyl; r is 0; s is 0; and n is 1 or 2; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
6. A pharmaceutical composition according to Claim 5, comprising any compound in accord with formula (I), wherein:
R1 is hydrogen, methyl, ethyl or allyl;
R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, moφholino, 4- methylpiperazin-1-yl, or l,2,3,4-tetrahydroisoquinol-2-yl ring; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
7. A pharmaceutical composition according to Claim 6, comprising any compound in accord with formula (I), wherein: R1 is methyl;
R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen to which they are attached in combination form a piperidin-1-yl, moφholino or 1 ,2,3,4-tetrahydroisoquinol-2-yl ring; or a pharmaceutically-acceptable salt or and in vzvo-hydrolysable ester, amide or carbamate thereof.
Any compound according to formula (I):
(I) wherein:
R1 is hydrogen, C,.6alkyl, C2.6alkenyl or C2.6alkynyl;
R2 and R3 are independently selected from hydrogen, C,.6alkyl, C2.6alkenyl, C2. 6alkynyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3.12cycloalkyl and C3. 12cycloalkyl fused to a benzene ring, wherein said C,.6alkyl, C2.6alkenyl, C2.6alkynyl, are optionally substituted with one or more groups selected from halo, nitro, hydroxy, C,.6alkoxy, cyano, amino, trifluoromethyl, trifluoromethoxy, carboxy, carbamoyl, mercapto, sulphamoyl, mesyl, N-C,.6alkylamino, N,N-(C,.6alkyl)2amino, C,.6alkoxycarbonyl, N-C,.6alkylcarbamoyl, N,N-(C,_6alkyl)2carbamoyl, aryl, a carbon linked heteroaryl, a carbon-linked heterocycle, C3. I2cycloalkyl and C3.12cycloalkyl fused to a benzene ring; and wherein any aryl, heteroaryl, heterocycle, C3.12cycloalkyl and C3.,2cycloalkyl fused to a benzene ring may be optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N-
(C,.6alkyl)amino, NN-(C,_6alkyl)2amino, C,.6alkanoylamino, N-(C,.6alkyl)carbamoyl, NN-(C,.
6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,.6alkoxycarbonyl, N-(C,. 6alkyl)sulphamoyl, NN-(C,.6alkyl)2sulphamoyl and phenylC, .6alkyl; and a heterocycle or a heteroaryl ring containing an -ΝH- group may be optionally substituted on this nitrogen with
C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C,.6alkylsulphonyl or phenylC,.6alkyl; or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring and wherein said heterocyclic or heteroaryl ring is optionally substituted on a ring carbon with one or more groups selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,-6alkoxy, C,.6alkanoyl, C,.6alkanoyloxy, N-
(C,.6alkyl)amino, N.N-(C,.6alkyl)2amino, C,.6alkanoylamino, N-(C,.6alkyl)carbamoyl, NN-(C,.
6alkyl)2carbamoyl, C,.6alkylS(O)a wherein a is 0, 1 or 2, C,.6alkoxycarbonyl, N-(C,. 6alkyl)sulphamoyl, NN-(C,.6alkyl)2sulphamoyl or phenylC, .6alkyl; and a heterocyclic or a heteroaryl ring containing an -ΝH- group is optionally substituted on this nitrogen with C,.
6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkanoyl, C,.6alkylsulphonyl;
R4 is selected from halo, hydroxy, C,.6alkyl, C,.6alkoxy, haloC,.6alkyl, cyano, nitro or
C2.6alkenyl; R5 is C,.6alkyl; n is 1 or 2; r is 0, 1, 2, 3 or 4, wherein at each occurrence the values of R4 may be the same or different; and s is 0, 1, 2 or 3 wherein at each occurrence the values of R5 may be the same or different; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof; with a proviso wherein in such compounds: if R' is hydrogen, R2 and R3 and the nitrogen to which they are attached in combination form a moφholine or piperidine ring, n is 1 and s is 0, then r is not 0, or R4 is not a 5 -linked ethoxy moiety.
9. A compound according to Claim 8, wherein: R1 is hydrogen, C,.6alkyl or C2.6alkenyl;
R2 and R3 are independently selected from hydrogen, aryl and C,.6alkyl optionally substituted with aryl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a heterocyclic or heteroaryl ring wherein a heterocyclic ring containing an - NH- group may be optionally substituted on this nitrogen with C,.6alkyl; r is 0; s is 0; and n is 1 or 2; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
10. A compound according to Claim 9, wherein: R1 is hydrogen, methyl, ethyl or allyl;
R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen atom to which they are attached in combination form a piperidin-1-yl, moφholino, 4- methylpiperazin-1-yl, or l,2,3,4-tetrahydroisoquinol-2-yl ring; or a pharmaceutically-acceptable salt or an in vzvo-hydrolysable ester, amide or carbamate thereof.
11. A compound according to Claim 10, wherein: R1 is methyl;
R2 and R3 are independently selected from methyl or benzyl, or R2 and R3 and the nitrogen to which they are attached in combination form a piperidin-1-yl, moφholino or 1 ,2,3,4-tetrahydroisoquinol-2-yl ring; or a pharmaceutically-acceptable salt or and in vzvo-hydrolysable ester, amide or carbamate thereof.
12. A compound according to Claim 8, selected from:
4-(2-(piperidin- 1 -yl)ethyl(N-methyl)amino)thiochroman; 4-(2-(moφholino)ethyl(N-methyl)amino)thiochroman;
4-(2-(piperidin- 1 -yl)ethyl(N-ethyl)amino)thiochroman;
4-(2-(moφholino)ethyl(N-allyl)amino)thiochroman;
(-)-4-(2-(l,2,3,4-tetrahydroisoquinolin-2-yl)ethylamino)thiochroman; 4-(3 -moφholin-4-ylpropylamino)thiochroman;
4-(2-dimethylaminoethylamino)thiochroman;
4-(2-isopropylaminoethylamino)thiochroman;
4-((2-pyrrolidin- 1 -ylethyl)amino)thiochroman;
4-(2-diethylaminoethylamino)thiochroman; 4-((3-piperidin- 1 -ylpropyl)amino)thiochroman;
4-((3-(4-methylpiperazin- 1 -yl)propyl)amino)thiochroman;
4-(2-phenylaminoethylamino)thiochroman;
4-(2-benzylaminoethylamino)thiochroman;
4-(methyl-(3-(4-methylpiperazin- 1 -yl)propyl)amino)thiochroman; 4-(ethyl-(2-moφholin-4-yl-ethyl)amino)thiochroman;
(R)-4-(2-(3 ,4-dihydro- 1 H-isoquinolin-2-yl)ethyl)amino)thiochroman;
(S)-4-(N '-(2-(3 ,4-dihydro- 1 H-isoquinolin-2-yl)-N-ethyl)amino)thiochroman;
(R)-4-(N'-(2-(3 ,4-dihydro- lH-isoquinolin-2-yl)-N-ethyl)amino)thiochroman;
(S)-4-(N-2-(N'-benzyl-N-methylamino)ethyl(N-methyl)amino)thiochroman; (S)-4-(N'-methyl-N'-(2-pyrrolidin- 1 -y lethy l)amino)thiochroman;
(S)-4-(N'-(2-(l,3-dihydroisoindol-2-yl)ethyl)-N'-methylamino)thiochroman;
(S)-4-(N'-(2-(l,3-dihydroisoindol-2-yl)ethyl)amino)thiochroman;
(S)-4-((2-azepan-l -ylethyl)amino)thiochroman, and
(S)-4-(2-(N'-benzyl-N-methylamino)ethylamino)thiochroman.
13. A method of making a compound of formula (I) according to Claim 8, wherein R'
R2, R3, R4, R5, s, r and n unless otherwise defined are as defined in Claim 8, said method comprising: a) reacting a ketone of formula (II):
(ii) with an amine of formula (III):
(in); wherein Rb and Rc are R2 and R3 respectively, unless the value of R2 and/or R3 is hydrogen, in which case the appropriate Rb and/or Rc is a suitable amino protecting group such as those defined below; or b) reacting an amine of formula (IV):
(IV) with an aldehyde of formula (V):
(V) wherein Rb and Rc are as defined above; or c) reacting an aldehyde of formula (VI): with an amine of formula:
R2
I HN.
"R3
(NH) wherein Ra is R1 unless the value of R1 is hydrogen, in which case Ra is a suitable amino protecting group such as those defined below; or d) if R1 is C,.6alkyl, reacting a compound of formula (VIII):
(VIII) wherein Rb and Rc are as defined above, with a compound of formula (IX);
(IX) wherein K is hydrogen or C,.5alkyl; or e) reacting a compound of formula (X):
(X) wherein L is a suitable displaceable group, with an amine of formula (III); or f) reacting an amine of formula (IV) with a compound of formula (XI):
(XI) wherein L is a suitable displaceable group and Rb and Rc are as defined above; or g) reacting a compound of formula (XII):
(XII) wherein L is a suitable displaceable group, with an amine of formula (VII); or h) if R1 is not hydrogen, reacting a compound of formula (VIII) with a compound of formula (XIII):
R'-L
(XIII) wherein L is a suitable displaceable group; or i) reducing a compound of formula (XIV):
or j) reducing a compound of formula (XV):
or k) if R1 is not hydrogen, reducing a compound of formula (XVI):
(XVI) wherein: to prepare a compound wherein R1 is methyl, G is a suitable displaceable group; to prepare a compound wherein R1 is C2.6alkyl, G is C,.5alkyl; and thereafter if necessary: converting a compound of the formula (I) into another compound of the formula (I); removing any protecting groups; and forming a pharmaceutically-acceptable salt or in vzvo-hydrolysable ester, amide or carbamate.
EP00942179A 1999-06-17 2000-06-14 Thiochroman derivatives resisting neurological disorders Withdrawn EP1192148A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9914015 1999-06-17
GBGB9914015.4A GB9914015D0 (en) 1999-06-17 1999-06-17 Chemical compounds
PCT/GB2000/002312 WO2000078744A1 (en) 1999-06-17 2000-06-14 Thiochroman derivatives against neurological disorders

Publications (1)

Publication Number Publication Date
EP1192148A1 true EP1192148A1 (en) 2002-04-03

Family

ID=10855465

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00942179A Withdrawn EP1192148A1 (en) 1999-06-17 2000-06-14 Thiochroman derivatives resisting neurological disorders

Country Status (5)

Country Link
EP (1) EP1192148A1 (en)
JP (1) JP2003502417A (en)
AU (1) AU5689300A (en)
GB (1) GB9914015D0 (en)
WO (1) WO2000078744A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260113B2 (en) * 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
DK1751111T3 (en) 2004-03-01 2015-02-09 Actelion Pharmaceuticals Ltd SUBSTITUTED 1,2,3,4-tetrahydroisoquinoline derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687401B1 (en) * 1992-02-18 1994-05-20 Meram Laboratoires 1,4-DIALKYLPIPERAZINE DERIVATIVES, PROCESSES FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
DE69715865T2 (en) * 1996-07-01 2003-08-07 Schering Corp., Kenilworth Muscarinic Antagonists
GB9801812D0 (en) * 1998-01-29 1998-03-25 Zeneca Ltd Chemical compounds
GB9900078D0 (en) * 1999-01-05 1999-02-24 Zeneca Ltd Chemical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0078744A1 *

Also Published As

Publication number Publication date
AU5689300A (en) 2001-01-09
WO2000078744A1 (en) 2000-12-28
JP2003502417A (en) 2003-01-21
GB9914015D0 (en) 1999-08-18

Similar Documents

Publication Publication Date Title
TWI242004B (en) 1-(1-substituted-4-piperidinyl)methyl-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
EP0738262B1 (en) Novel heterocyclic compounds
JP3534765B2 (en) Novel 4-piperidinyl-substituted lactams as neurokinin 2 receptor antagonists for the treatment of asthma
IE831730L (en) Quinoline derivatives
EA007225B1 (en) Derivatives of n-[phenyl(piperidin-2-yl)methyl]benzamide and application of same in therapeutics
AU684874B2 (en) Heterocyclic compounds for the treatment of cns and cardiovascular disorders
JP2011519913A (en) A new class of spiropiperidines for the treatment of neurodegenerative diseases
WO2000078742A1 (en) Chroman derivatives against neurological disorders
WO2004002483A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer’s disease
EP1192148A1 (en) Thiochroman derivatives resisting neurological disorders
JP2918508B2 (en) Azetidines
EP1060169A1 (en) 1,4-diazacycloheptane derivatives
EP0777660A1 (en) Novel alkylamino derivatives as sigma 2 selective ligands
US4873236A (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
WO2000035882A1 (en) 1,2,3,4-tetrahydronaphthalenes and their pharmaceutical use
SK286977B6 (en) Morpholine derivates, method for the production thereof and pharmaceutical preparations containing said derivates
US6407093B1 (en) 1,4-Diazacycloheptane derivatives for the treatment of neurological disorders
WO2000078751A2 (en) Compounds for use in treatment of neurological disorders
EP1140880A1 (en) Homopiperazine derivatives as selective emopamil inhibitors
WO2000078736A1 (en) 1,4-diazacycloheptane derivatives as neuroprotective agents
EP1204641A1 (en) 4-aminopiperidine derivatives of tetrahydronaphthalene, chromans and thiochromans
WO2000039105A1 (en) 1,4-diazacycloheptane derivatives useful in the treatment of neurological disorders
EP1140891A1 (en) 1,4-diazacycloheptane compounds, process for their preparation, and their use as medicaments
CA2501552A1 (en) Substituted aminoquinuclidine compounds
WO2002051793A1 (en) Sterol isomerase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020510

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020921